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ABSTRACT 
Sickle cell disease (SCD) is one of the most common hemoglobinopathies 
worldwide.  It is caused by a homozygous mutation in codon 6 of the beta globin gene 
(HBB), which leads to polymerization of the variant hemoglobin and sickled red blood 
cells that obstruct blood vessels and reduce oxygen delivery to tissues.  Patients with 
SCD have multiple clinical problems, including pain crises, anemia and organ damage.  
However, not all patients with SCD display all these clinical manifestations.  One major 
factor for reduced occurrences of symptoms is fetal hemoglobin (HbF).  HbF is the main 
hemoglobin in the fetus, and declines one year after birth to less than one percent of total 
hemoglobin.  Nevertheless, there are individuals who continue to have high levels of HbF 
into adulthood, which is beneficial for an individual with SCD because HbF reduces the 
amount of sickle polymer in red blood cells.  There are three major quantitative trait loci 
(QTL) associated with high HbF.  However, these QTL account for 20-45% of HbF 
variance.  Therefore, further investigation is required to fully understand how HbF is 
regulated. 
  x 
The HBS1L-MYB intergenic polymorphism (HMIP) on chromosome 6q23 is one 
of the major QTL associated with high HbF.  This region is also known to regulate other 
erythroid-specific traits due to an enhancer element that promotes the expression of the 
downstream gene, MYB, which controls hemoglobin expression and erythroid 
proliferation and maturation.  The presence of RNA polymerase II binding and a 50-bp 
transcript suggested that a long noncoding RNA (lncRNA) is transcribed from this 
region.  LncRNAs are non-protein-coding transcripts greater than 200 nucleotides and are 
involved in gene regulation.  Therefore, it was hypothesized that a lncRNA is transcribed 
from the enhancer of MYB and regulates hemoglobin expression. 
I characterized a novel lncRNA, 1283 bp in length that was differentially 
expressed among various tissue types, among erythroid progenitor cells with different 
hemoglobin makeup, and also during erythroid differentiation.  Furthermore, knockdown 
of this lncRNA, named the HBS1L-MYB intergenic long noncoding RNA (HMI-
LNCRNA), significantly increased HbF.  Taken together, these observations suggest that 
HMI-LNCRNA can be a possible therapeutic target to increase HbF expression in patients 
with SCD and β-thalassemia. 
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CHAPTER 1.  INTRODUCTION 
1.1 Red Blood Cells 
Cellular respiration—the set of metabolic processes that convert the nutrients we 
consume into energy—is required to sustain all the biological functions of the human 
body.  However, energy can only be provided if oxygen is available.  The presence of 
oxygen is controlled by the circulatory system, in which the heart pumps blood 
throughout the body.  Three types of cells are found in the blood—leukocytes, 
thrombocytes and erythrocytes.  Erythrocytes, also known as red blood cells (RBCs), are 
red, round, biconcave cells, are the most common cell type in the blood, and carry 
oxygen to tissues throughout the body.  The process by which this occurs begins in the 
lungs, where the oxygen that is inhaled through the lungs is absorbed by RBCs.  Once in 
the RBC, oxygen binds to the heme group that is attached to globin.1  Next, RBCs 
circulate through the vascular system, releasing oxygen to all vital organs.  Since RBCs 
are so important to human life, it is essential to know and understand how they are 
developed—a process called erythropoiesis—and the main protein content responsible 
for their function—hemoglobin. 
1.1.1 Erythropoiesis 
The ontogeny of erythropoiesis changes while the human embryo is developing in 
the womb.  Collectively, there are two types of erythropoiesis—primitive and 
definitive—and three sites of origin for RBCs—the yolk sac, liver and bone marrow.2–4  
For both primitive and definitive erythropoiesis, the basic order of these processes is to 
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expand or proliferate erythroid precursors from progenitor cells, promote expression of 
hemoglobin, decrease cell size, enucleate and function as a red blood cell in circulation.  
However, the type of progenitors these cells are derived from and the location of 
erythroid differentiation differs between these two processes (Figure 1.1A). 
Primitive erythropoiesis begins 15 days after fertilization within the yolk sac.2,3  
Hemangioblast progenitor cells derived from the mesoderm differentiate in the yolk sac 
into primitive erythroid progenitor cells (EryP-CFC), which form into clusters of cells 
called “blood islands.”5  Next, these erythroid progenitor cells are released into blood 
vessels and differentiate further as four different erythroblast precursors that are named 
based on the morphology of the cells.  In the order of maturation, they are 
proerythroblasts (ProE), basophilic erythroblasts (BasoE), polychromatophilic 
erythroblasts (PolyE) and orthochromatic erythroblasts (OrthoE), during which the 
erythroblasts’ nuclei condense, the cell size decreases and hemoglobin production 
increases (Figure 1.1B).2,6  As OrthoE, the erythroblasts enucleate and become 
reticulocytes, and then achieve terminal maturation into RBCs indicated by the biconcave 
disc shape of the cell membrane.7,8 
Definitive erythropoiesis occurs in both the liver and bone marrow.2  However, 
the source of progenitor cells is different in both locations.  In the liver, erythroblast 
precursors called burst-forming units erythroid (BFU-E) are originally from the yolk 
sac.9,10  In the yolk sac, at around 4 to 5 weeks of gestation, erythro-myeloid progenitors 
(EMPs), which are multipotent hematopoietic progenitor cells, differentiate into BFU-E.  
Once expansion of BFU-E occurs, they are released into circulation and migrate to the 
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liver.  Concurrently, hematopoietic stem cells (HSCs) begin to emerge from the aorta-
gonad-mesonephros (AGM) region, and also travel to and expand in the fetal liver.  At 10 
to 11 weeks of gestation, HSCs begin to travel from the liver to the bone marrow, where 
they will permanently stay.  This transition continues until after birth, when the bone 
marrow becomes the only source of red blood cells for the duration of life.  In both the 
fetal liver and bone marrow, HSCs give rise to BFU-E, which will give rise to another 
erythroid precursor called colony-forming unit erythroid (CFU-E).  Both are named based 
on their morphology when they are cultured in vitro in semisolid medium.  Next, 
erythroid maturation occurs in the same order as primitive erythropoiesis.  However, 
maturation does not occur in the blood vessel.  It occurs in the fetal liver and bone 
marrow within erythroblastic islands, which are made up of erythroblasts that are 
physically attached to macrophages.11  Once the OrthoE enucleate, reticulocytes are 
formed and released into the bloodstream where they terminally maturate into RBCs.  
The lifespan of a RBC is 120 days, and thereafter senesce and are removed by 
macrophages located in the spleen.2 
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Figure 1.1.  Erythropoiesis. 
(A) Illustration of the direction of erythropoiesis from progenitor cells in the fetal liver 
and bone marrow (definitive), and progenitor cells in the yolk sac (primitive).  During 
definitive erythropoiesis, erythroid differentiation and maturation occurs in the fetal liver 
or bone marrow until enucleation occurs, and the reticulocyte is released into the blood to 
undergo terminal maturation into a red blood cell.  During primitive erythropoiesis, 
progenitor cells are released from the yolk sac and into the blood where they undergo 
erythroid differentiation from erythroblasts to red blood cells.  Image adapted from Palis, 
Frontiers in Physiology 2014.  (B) Morphology of human erythroblasts as 
proeythroblasts (ProE), basophilic erythroblasts (BasoE), polychromatophilic 
erythroblasts (PolyE) and orthochromatic erythroblasts (OrthoE).  Image adapted from 
Palis, Blood 2014. 
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The most important driver of erythroid maturation is erythropoietin (EPO).2,9,12  
EPO is a cytokine that is released from the kidneys when RBC count is low, and binds to 
the erythropoietin receptors (EPOR) of CFU-E to promote differentiation.  During 
erythroid maturation, two markers of maturation are expressed—transferrin receptor 
(CD71) and glycophorin A (CD235a).10  CD71 is a marker for early erythroid maturation, 
and it is found in the plasma membrane of erythroblasts to promote uptake of iron within 
the cell.13  This iron will help create the heme group that will be attached to globin to 
form hemoglobin that can reversibly bind oxygen.  As the erythroblasts mature they also 
begin to express CD235a, which is another protein found in the plasma membrane of 
erythroblasts, as well as mature RBCs.  CD235a contains sialic acid, which makes the 
RBCs hydrophobic.  This allows the RBCs to flow through the blood without adhering to 
blood vessels and other cells.  Once erythroid cells become fully mature RBCs, they lack 
expression of CD71 and only express CD235a. 
1.1.2 Hemoglobin switching 
Hemoglobin is a protein expressed by RBCs to bind to the oxygen that will be 
delivered to tissues in the entire body.  It is made up of four subunits of globin chains, 
with each subunit bound to a heme group, which is necessary for oxygen transportation.  
From the development of the first RBCs derived from the yolk sac to the RBCs that are 
ultimately made from the bone marrow, the type of hemoglobin expressed changes, and 
this is known as “hemoglobin switching.”14–16  Hemoglobin switching can also occur as 
the erythroblasts mature into RBCs, and is called “maturational switching.”17  This is due 
to the regulation of gene expression on two loci—the alpha (α) globin gene cluster on 
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chromosome (chr) 16p13.3, and the beta (β) globin gene cluster on chr11p15.  The 
functional genes of the α-globin gene cluster are made up of zeta (ζ) globin (HBZ) and 
two α-globin genes (HBA2, HBA1)18; and the β-globin gene cluster contains epsilon (ε) 
globin (HBE), two gamma (γ) globin (HBG2, HBG1), delta (δ) globin (HBD), and β-
globin (HBB) genes.19  On both loci, the direction of globin gene expression moves from 
the 5’ end to the 3’ end.  Hemoglobin is composed of two subunits from the α-globin 
gene cluster and two subunits from the β-globin gene cluster.  During primitive 
erythropoiesis, erythroblasts derived from the yolk sac undergo a maturational switch that 
occurs between five to seven weeks of gestation.17  The switch is only made within the α-
globin gene cluster, from hemoglobin Gower I (ζ2ε2) to hemoglobin Gower II (α2ε2).  At 
around three months of gestation, when the fetal liver begins to take over RBC 
production, the switch is now within the β-globin gene cluster, and the cells make fetal 
hemoglobin (HbF) (α2γ2).  HbF expression continues when the location of definitive 
erythropoiesis changes to the bone marrow.  However, HbF does not remain the most 
abundant hemoglobin, and another switch occurs within the β-globin locus.  After birth, 
HbF declines while adult hemoglobin (HbA1) (α2β2) increases as the main type of 
hemoglobin expressed in RBCs.  Another type of adult hemoglobin (HbA2) (α2δ2) is also 
made, but in small quantities.  Eventually, the hemoglobin makeup in an adult becomes 
less than 1% HbF, 2.5% HbA2 and 95.5% HbA1. 
  
  
7 
 
 
 
 
 
 
 
Figure 1.2.  Hemoglobin Switching. 
(A) Globin chains are transcribed from both the alpha globin gene cluster on 
chromosome 16 and the beta globin gene cluster on chromosome 11.  (B) Genes on both 
loci are differentially expressed during gestation, and translates into individual globin 
subunits that form into a tetramer to make embryonic, fetal or adult hemoglobin (C).  
Chart in (B) is adapted from Forget, N Engl J Med 2011. 
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1.1.3 Transcription factors that regulate erythropoiesis and hemoglobin switching 
Primitive and definitive erythropoiesis, and hemoglobin switching are regulated 
by the expression pattern of key transcription factors.  GATA1, KLF1, TAL1, LMO2 and 
LDB1 are all expressed during primitive and definitive erythropoiesis.2,4,20,21  They not 
only regulate hemoglobin expression but also erythroid maturation.  GATA1 promotes 
erythropoiesis by regulating the expression of erythroid-specific genes.  It does so by 
working in complex with TAL1, LMO2 and LDB1.  Loss of GATA1 inhibits the 
maturation of erythroblasts.22  KLF1 is another regulator of erythropoiesis as well as 
hemoglobin production.23  It controls the expression of other erythroid-specific genes to 
promote expression of both embryonic and adult hemoglobin, stabilizes α-globin, ensures 
the biosynthesis of heme, and regulates other transcription factors. 
The differences between primitive and definitive erythropoiesis are the expression 
of additional transcriptions factors only during the definitive stage (Table 1.1).  These 
transcription factors work mostly to regulate expression of genes on the β-globin gene 
locus via the locus control region (LCR) that is located upstream this region.  The LCR is 
a super enhancer with five DNase I-hypersensitive sites (HSs), which interacts with 
promoters of the downstream globin genes to promote their expression.24  However, 
which promoter it will interact with depends on the expression of key transcription 
factors.  c-MYB is one of these transcription factors that have been shown to promote 
erythropoiesis and work in complex with other transcription factors on the β-globin locus 
to reduce expression of γ-globin genes HBG1 and HBG2.25–29  The next transcription 
factor, SOX6, is a Sry-related high-mobility group (HMG) box transcription factor, and 
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has been shown to directly bind to the promoter of HBE to repress its expression.30  The 
last transcription factor, BCL11a, contains zinc fingers that bind directly to the LCR and 
multiple sites on the β-globin gene cluster to specifically reduce expression of HBG and 
increase expression of the HBB.31–34  It has been shown to do so by working with other 
transcription factors, including SOX6.35 
 
Table 1.1.  Globin genes and transcriptions factors that are expressed during 
primitive and definitive erythropoiesis 
Table adapted from Palis, Blood 2014. 
 Primitive 
Erythropoiesis 
Definitive 
Erythropoiesis 
Globin Genes HBZ and HBA1 HBE and HBG 
HBA1 
HBB 
Transcription Factors GATA1, KLF1, TAL1, LMO2 and LDB1 
GATA1, KLF1, TAL1, 
LMO2, LDB1, c-MYB, 
SOX6, and BCL11a 
 
 
Taken together, RBCs are vital to human life, and require regulated processes at 
both the biological and molecular levels to ensure that healthy RBCs are developed and 
have the ability to effectively transport oxygen throughout the body. 
1.2 Sickle Cell Disease 
Genetic variants or mutations within both the α-globin and the β-globin loci, and 
transcription factors that regulate erythroid-specific traits can threaten erythropoiesis, 
hemoglobin expression and/or the viability of RBCs, and cause various blood disorders 
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or hemoglobinopathies.18,36,37  One of these blood disorders is called sickle cell disease 
(SCD). 
SCD was first described in 1910 by a cardiologist named James B. Herrick who 
saw that the appearance of RBCs from his patient was abnormal.  However, Herrick 
could not decipher whether the patient had a primary blood disorder or whether the 
peculiar shaped cells occurred because of another clinical disorder.38–40  It was not until 
1945 that Linus Pauling hypothesized that sickled RBCs were due to defects within the 
hemoglobin, and in 1949 Pauling and others showed by gel electrophoresis that 
hemoglobin from sickle cells migrate differently than hemoglobin from normal cells, thus 
proving that his hypothesis was indeed correct.40–42  Later that year, it was established 
that SCD can be inherited and as an autosomal recessive trait.  However, the exact 
mutation of SCD was still not known.  Ten years later, Vernon Ingram established that 
SCD is due to a mutation of codon 6 of HBB, which causes a change in an amino acid of 
adult hemoglobin (HbA1) (glutamic acid to valine).43 
Since then, with more understanding of erythropoiesis and hemoglobin switching, 
scientists were able to establish the pathophysiology of SCD.  One aspect of SCD that 
was not quite understood during the earlier years of study is the sickled shape.  The 
glutamic acid-to-valine change turns HbA1 to sickle hemoglobin (HbS), where the two β-
chains found in HbA1 (α2β2) becomes sickle β-globin (βS).44,45  This modifies the 
properties of hemoglobin produced in RBCs because valine is more hydrophobic than 
glutamic acid.  When an RBC releases its oxygen, it is deoxygenated.  In a RBC with 
normal hemoglobin, deoxygenation does not modify the structure of the hemoglobin 
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molecule.  However, in a RBC with HbS, deoxygenation causes the more hydrophobic 
hemoglobin to polymerize.  This leads to disruption of the cytoskeleton and protrusion of 
HbS polymer through the cell membrane, and is the reason sickle RBCs display many 
abnormal morphological characteristics.  Damage to the cell membrane alternates the 
transmembrane proteins and the lipid bilayer, consequently changing many properties of 
the RBC.  Normal RBCs can flow freely in circulation, without attaching to blood vessels 
and other cells.  However, sickled RBCs undergo hemolysis, and attach to both the 
endothelium of blood vessels and other cells, and this promotes vascular occlusion 
(Figure 1.3).46–48  Hemolysis and vaso-occlusion of sickle RBCs leads to acute pain 
crises, anemia and organ damage due to tissue oxygen deprivation.  Other symptoms of 
SCD are swelling of the hands and feet, bacterial infection and acute chest syndrome.  
SCD is associated with premature death.  Another aspect of SCD is the timeline when 
symptoms occur.  Babies born with SCD do not show clinical evidence of the disease 
until sometime after the first three to six months of life.  This is due to hemoglobin 
switching.  After birth, the main type of hemoglobin a baby makes is HbF.  However, 
during that first year of life, HbF significantly reduces while HbA1 becomes the main 
type of hemoglobin expressed in RBCs.  In an infant homozygous for the mutation of 
codon 6 in HBB, it is HbS, not HbA1 that is mainly expressed.  Therefore, clinical 
symptoms related to SCD are delayed while HbF is still high, and do not start until HbF 
is replaced by HbS. 
  
  
12 
 
 
 
 
 
 
Figure 1.3.  Sickle Cell Disease. 
(A) Peripheral blood smear from a patient with sickle cell disease, stained with May-
Grunwald-Giemsa.  Red blood cells displaying a sickled shape (S) are distinct from 
normal round red blood cells.  Image adapted from Rees et al, The Lancet 2010.  (B) 
Illustration of how red blood cells with normal hemoglobin can flow freely through blood 
vessels, compared to red blood cells with sickle hemoglobin, which cause vaso-occlusion.  
Image adapted from NIH/NHLBI website (https://www.nhlbi.nih.gov/health/health-
topics/topics/sca). 
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1.2.1 Epidemiology of SCD 
  SCD has become one of the most common inherited hemoglobinopathies 
worldwide.44,45,49  Originally, SCD was mostly found in populations of people located in 
regions where malaria was endemic.50  When individuals heterozygous for the sickle 
mutation—also known as having sickle cell trait—are infected with malaria, they have 
increased survival and are able to reproduce.  Public health initiatives to decrease the 
incidence rate of malaria and other infectious diseases, and to promote better clinical 
practices within these regions have also increased the lifespan of people with SCD.  
Furthermore, the rise in human migration from these regions has now made SCD a global 
health problem.  SCD is a prime example of a genetic balanced polymorphism; increased 
fitness (survival, reproduction) of the heterozygote is accompanied by decreased fitness 
of the homozygote. 
SCD is mostly found in people of African, Arabian and Indian descent.  Globally, 
about 300,000 newborns are born with SCD each year, and it has been projected that it 
will rise to about 400,000 newborns by 2050.49  The highest incidence rate of SCD is 
found in West Africa, with up to 90,000 babies born with the disease per year in Nigeria 
alone (the highest rate worldwide).51  In the United States of America (USA), 
approximately 100,000 people have SCD; one out of 365 African American (AA) babies 
are born with SCD; and one out of 13 AA babies are born with the sickle cell trait.52 
1.2.2 HbF and SCD 
The delayed appearance of sickle RBCs and the clinical manifestations of disease 
that hematologists observed throughout the first year after birth of infants with SCD led 
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them to consider HbF as a key factor for this delay.  Subsequently, laboratory studies 
discovered that HbF inhibits the polymerization of HbS by obstructing the formation of 
HbS polymer in RBCs.52  The tetramer that makes up HbS is α2βS2.  However, when γ-
globin is also expressed, the HbF molecule α2γ2 is excluded from the HbS polymer, and 
the mixed hybrid tetramer α2βSγ, has reduced incorporation into the polymer.  Together, 
this reduces the polymerization potential of HbS leading to more normal RBCs. 
SCD patients display a wide range of disease severity.  Also different among SCD 
patients is the percent of HbF—some with nearly normal HbF, and others with higher 
levels of HbF.  Epidemiological studies, which looked at the natural history of SCD, 
found that patients with SCD and high HbF have lower disease burden than SCD patients 
with lower HbF.  One such study is the Cooperative Study of Sickle Cell Disease 
(CSSCD), which prospectively studied the natural history of about 4,000 patients in 23 
health facilities around the US.53–55  Funded by the National Heart, Lung, and Blood 
Institute (NHLBI) at the National Institutes of Health (NIH), the CSSCD found that 
various complications of SCD, including death, were reduced in patients with HbF > 
8.6%.  Taken together, SCD patients benefit from having high expression of HbF, and 
this is due to the inhibitory effects it has on the polymerization of HbS. 
1.2.3 Prevention and treatment of SCD 
There are preventive measures to reduce the incidence rate of SCD.  Programs for 
premarital, antenatal and neonatal screenings determine if both individuals who are 
engaged to get married have the sickle cell trait, and if an unborn child or a newborn 
child has SCD.44  This will allow couples to make an informed decision about whether to 
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continue with their nuptials or to have children if they are both carriers of the sickle cell 
trait; allow for antenatal diagnosis that will provide a choice to continue with the 
pregnancy if the fetus is found to have SCD; and will alert clinical professionals to 
newborns born with SCD in order to monitor and start treatment at an earlier time. 
As for therapeutic treatments for SCD, there are two United States (US) Food and 
Drug Administration (FDA)-approved drugs to treat SCD.  First approved is 
hydroxyurea.  Hydroxyurea was initially used as a chemotherapeutic agent to treat 
myeloproliferative disorders.  Scientists found that hydroxyurea treatment increased HbF 
levels in baboons56, and therefore started clinical trials to determine if it is helpful for 
patients with SCD, leading to it being the standard of treatment.57–61  However, the 
mechanism of how hydroxyurea upregulates HbF is not clearly understood.  Furthermore, 
not all SCD patients respond to hydroxyurea treatment.  Recently, L-glutamine, given as 
daily supplement, was associated with reduced vaso-occlusive crises and was FDA 
approved.62  Whether or not this will change the standard of care is unclear. 
Blood transfusions are another form of treatment, which reduces the percent of 
sickle cells in circulation by giving the patient healthy RBCs.  Even though blood 
transfusions are effective, it is a burden because patients have to frequently have this 
procedure.63–65  Also, patients who undergo frequent blood transfusions can develop 
antibodies against red cell antigens from transfused blood.  Furthermore, only individuals 
living in countries with a good health care structure will be able to access this treatment. 
A curative form of treatment is bone marrow transplantation, which replaces the 
bone marrow of SCD patients with bone marrow from healthy individuals, thus 
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substituting abnormal HSCs with normal HSCs.66  The limitations with this procedure are 
that complications can be fatal, it is expensive and there are few suitable donors.  An 
approach taken to address the lack of donors is gene therapy.  Gene therapy takes 
autologous HSCs, infects them with a self-inactivating lentiviral vector that encodes a 
variant for β-globin chain (T87Q substitution), which inhibits the polymerization of HbS, 
and engraft the transduced HSCs into the bone marrow of the patient.67  Recently, a case 
study was published about the 15-month follow-up of an SCD patient who underwent 
gene therapy.68  Not only did high expression of the variant β-globin persist, the patient 
had no sickle crises.  Gene therapy is a promising treatment, but the remaining two 
limitations of bone transplantation still is a concern. 
1.3 HbF Variability 
The observation that HbF is differentially expressed in patients with SCD, and 
that it is beneficial for patients to have higher levels of HbF, have steered researchers to 
determine the causes for this occurrence.  What has been elucidated as the main causes 
for high HbF are two types of genetic variants—deletions along the β-globin gene locus, 
and single nucleotide polymorphisms (SNPs) found in various regions of the genome.69  
These deletions have been named based on sequence of discovery, or the geographical 
location or ethnic group the variant is mostly prevalent. 
1.3.1 (δβ)0-thalassemia and hereditary persistence of fetal hemoglobin 
Numerous deletions have been discovered within the β-globin gene cluster.  Two 
types of deletions—(δβ)0-thalassemia and hereditary persistence of fetal hemoglobin 
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(HPFH)—are associated with high HbF.70,71  Multiple deletions have been characterized 
for each type; they vary in size, and new deletions continue to be discovered.  The 
deciding factors for what makes a deletion either a (δβ)0-thalassemia or an HPFH are the 
percentage of HbF that is expressed and the distribution of HbF among RBCs.  Adults 
with (δβ)0-thalassemia have HbF of 5-15% and it is distributed heterocellularly among 
RBCs, which means that not all cells have the same amount of HbF.  Conversely, adults 
with HPFH have higher levels of HbF (15-30%) and is distributed evenly or pancellularly 
among RBCs. 
The location and size variability has led to discoveries of cis-acting elements 
essential for globin switching.  The first element is a 3.5 (kilobase) kb intergenic region 
5-prime (5’) to the δ-globin gene (HBD), as has been found to be essential for the 
silencing of HBG expression via binding of Bcl11a and other transcription factors within 
this region.72  Consequently, a deletion within this region will increase HBG expression.  
Next, is the 3-prime (3’) HS1, which is a DNase1 hypersensitive site (HS) located 
downstream of HBB and is thought to be an insulator against enhancers for HBG.73  
Deletion of this region is also thought to increase HBG expression.  Last, are the three 3’-
enhancers, which are also downstream of HBB and have been found to enhance HBG 
expression.73  A deletion through HBB to a position 5’ to anyone of these enhancer 
regions is thought to bring the enhancer closer to HBG and increase its expression. 
1.3.2 The 3 major quantitative trait loci 
SNPs are single nucleotide variants and are found everywhere in the genome.  
Some SNPs do not change gene expression or epigenetic regulatory elements, while 
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others do.  Genome-wide association study (GWAS) is a tool used to determine which 
SNPs are significantly associated with a specific trait.  Since HbF is a trait that is 
beneficial for individuals with SCD, investigators have used GWAS to determine which 
SNPs are associated with high HbF, with the intent to determine if these SNPs could lead 
them to understand how HbF is regulated.74  Using GWAS, three regions of the genome 
have been revealed to be associated with high HbF.  These are the HBG2 promoter 
region, BCL11A, and the HBS1L-MYB intergenic region, and together are the three major 
quantitative trait loci (QTL) for HbF. 
First of these QTL to be discovered was the Xmn1-HBG2 C-T polymorphism 
located within the promoter of HBG2 158 base pairs (bp) upstream from the HBG2 
transcription start site (TSS).  This SNP creates an Xmn1 restriction site and is associated 
with increased expression of HBG2.19,75  The mechanism of action or the functional basis 
of this association is currently unknown.  The next region is BCL11A found on chr2p16, 
which encodes the transcription factor B-cell lymphoma/leukemia 11A (BCL11a).  As 
previously discussed (section 1.1.3,) BCL11a is a transcription factor that is important for 
the γ-globin to β-globin switch.76–79  SNPs found in intron 2 of BCL11A inhibit 
transcription of the gene, and therefore the hemoglobin switch does not occur, causing 
constitutive expression of HBG.  The last QTL is the HBS1L-MYB intergenic 
polymorphisms (HMIP) found on chr6q23, which consists of three HMIP trait-associated 
blocks with SNPs that are in linkage disequilibrium (LD).80,81  LD implies that SNPs are 
likely to be inherited with each other.  This QTL will be discussed further in the next 
section. 
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1.4 The HBS1L-MYB Intergenic Region 
The HBS1L-MYB intergenic region is 126 kb in length, and is in between the 
genes HBS1L and MYB.  HBS1L is a member of the GTP-binding elongation factor 
family with no known association with erythropoiesis or hemoglobin expression.  As 
discussed before (section 1.1.3), MYB encodes for the transcription factor c-MYB, and is 
known to regulate erythroid proliferation and maturation, and hemoglobin    
expression.25–27  There are many SNPs within this intergenic region, and for a while it 
was not understood why these SNPs were associated with high HbF.  Our lab was one of 
many laboratories to confirm the association of these SNPs with high HbF.82  Among a 
group of non-related Chinese individuals heterozygous for β-thalassemia, HbF variability 
was associated with known SNPs such as rs9399137.  What was novel was the discovery 
of a 3-bp deletion polymorphism (rs66650371), which is in LD with rs9399137 and 
therefore also associated with high HbF.  Additionally, it was discovered by chromatin 
immunoprecipitation (ChIP) around the 3-bp deletion that in K562 cells, an immortalized 
erythroid cell line, are binding sites for four transcription factors that are involved in 
erythroid cell differentiation, GATA, TAL1, E47 and RUNX1.  Also, Encyclopedia of 
DNA Elements (ENCODE) datasets revealed binding of RNA polymerase II and other 
factors such as Brg1 signaling, which signifies transcriptional activity, histone H3 lysine 
4 monomethylation (H3K4Me1) activity (marker for enhancer regions), and expression 
of a 50-bp transcript.  To confirm that this region was an enhancer, the fragment was 
cloned into a vector with an HBG2 promoter and a luciferase reporter gene.  Cells 
transfected with the fragment containing this region showed higher levels of luciferase 
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activity than cells cloned without this region.  We concluded that the 3-bp deletion within 
HMIP was associated with increased HbF production, had signatures of transcription 
activity very similar to erythroid-specific transcription activity, and contained an 
enhancer element. 
This work was later confirmed and extended by others who found that within the 
HMIP region was an enhancer region, which included the 3-bp polymorphism and 
binding sites for erythroid-specific transcription factors, and that the enhancer element 
actually regulated the expression of MYB.83,84  They determined the mechanism of how 
polymorphisms in this region were associated with high HbF, and showed that when this 
enhancer region is intact, it has the ability to bind to the promoter of MYB and upregulate 
its expression.  However, if the 3-bp polymorphism was present, the enhancer cannot 
bind to the promoter, resulting in a reduction in the expression of MYB and increase in 
HbF expression. 
1.5 Long Noncoding RNA 
The genome contains genes that are transcribed and processed into messenger 
RNAs (mRNAs), and these mRNAs are then translated into proteins to regulate the 
multiple processes in the cell.  However, it was discovered that while 50-70% of the 
genome is transcribed, only 2% is translated into protein.85  Except for transfer RNAs 
(tRNAs) and ribosomal RNAs (rRNAs), the other remaining untranslated RNAs were 
considered to have no biological function and were labeled as “junk RNAs.”  This was 
puzzling because many less complex species translate more of their genome, while more 
complex species, such as humans, translate less.  As next generation sequencing (NGS) 
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became a popular scientific tool to look at total RNA expression, scientists discovered 
that noncoding RNAs (ncRNAs) are differentially expressed during development and 
within various disease models.86  The discovery of changes in ncRNA expression patterns 
led to functional analyses to determine if modulation of ncRNA expression affect any 
downstream molecular or cellular activity.  Their findings showed that ncRNAs actually 
do regulate molecular and cellular activities, and therefore changed the dogma of 
ncRNAs—they do have biological functions.  There are various types of ncRNAs and 
among them are the long noncoding RNAs or lncRNAs. 
LncRNAs are transcripts of 200 nucleotides or greater that do not code for 
protein.87,88  They are transcribed from any region in the genome; low in abundance; 
mostly tissue-specific (more so than mRNA); located mostly in the nucleus of the cell; 
and can have many signatures of mRNA, such as the 5’-cap, 3’-polyadenylation and the 
ability to be spliced.89  Furthermore, they have been shown to regulate cellular processes 
at various levels.90,91  They can recruit epigenetic factors, control pluripotency, regulate 
transcription (in cis or trans) and translation, and be involved in post-transcriptional 
processing of mRNA.  There are various types of lncRNAs that are named based on 
location relative to neighboring protein-coding genes.92,93  Intergenic lncRNAs 
(lincRNAs) are located between two protein coding genes; antisense lncRNAs 
(alncRNAs) are transcribed complementary to a mRNA; intronic overlapping lncRNAs 
(ilncRNAs) are transcribed from the intronic region of mRNA; small RNA (sRNA) host 
lncRNAs (shlncRNAs) have sRNAs transcribed from their intronic regions; pseudogene 
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lncRNAs (plncRNAs) are transcribed from pseudogenes; and enhancer RNAs (eRNAs) 
are transcribed from the enhancer of an mRNA. 
1.5.1 Enhancer RNAs 
Enhancers are regions in the genome that when bound by transcription factors, are 
able to change the conformation of the chromatin in order to activate transcription of a 
gene.  Active enhancers are known to have transcriptional activity.  There are three 
reasons for enhancer transcription—noise, transcription-dependent effects, or RNA-
dependent effects.94  Noise is due to collision of Pol II with accessible chromatin, and 
does not have any biological function.  A transcription-dependent effect is when 
movement of Pol II causes the conformation of chromatin to change, and epigenetic 
processes such as histone acetylation and methylation occur.  This is eRNA-independent.  
eRNA-dependent effects are when transcripts derived from enhancer regions function to 
regulate transcription either in cis or trans.95–99  This effect is eRNA-dependent, where 
eRNAs recruit or bind coactivators or transcription factors, and at act as a scaffold to 
ensure binding of these proteins at the promoter of neighboring protein-coding genes to 
promote gene expression (Figure 1.4).95 
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Figure 1.4.  The function of an enhancer RNA (eRNA). 
In this illustration, long noncoding RNA, ncRNA-a7, is transcribed from the enhancer 
element for SNAI1 and acts as a scaffold to transcription factors bound to the gene’s 
promoter to promote transcription of SNAI1.  Image adapted from Ong and Corces, 
Nature Reviews, Genetics, April 2011. 
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1.5.2 Hematopoietic/Erythroid-associated long noncoding RNAs 
There are multiple lncRNAs found to regulate either hematopoiesis or 
erythropoiesis.93,100–111  Most of what is known has been studied mostly in murine-
derived cells.  Hu et al found that more than 400 putative mouse lncRNAs fluctuate 
during erythropoiesis.112  Functional studies on one lncRNA, named long intergenic 
noncoding RNA (lincRNA) erythroid prosurvival (LincRNA-EPS), discovered that it 
inhibits apoptosis to promote erythroid differentiation.  Other work characterized a 
variety of lncRNAs by using microarray analyses from the ENCODE datasets.111  Since 
the HOXA gene cluster is differentially expressed during granulocytic differentiation and 
is myeloid-specific, they looked for expression of intergenic transcripts within this cluster 
in human cell lines that are able to undergo granulocytic differentiation.  This laboratory 
was able to find a lncRNA, which they named HOTAIRM1, located between HOXA1 and 
HOXA2 genes.  During granulocytic differentiation, HOTAIRM1 is upregulated, and was 
dependent on the expression pattern of both HOXA1 and HOXA2.  Bertani et al looked 
for lncRNAs that are involved in epigenetic activation via Mixed lineage leukemia 1 
(MLL1), which is known to be vital for embryonic development and hematopoiesis.  
RNA-chromatin immunoprecipitation (RNA ChIP) along with DNA microarray (RNA 
ChIP-on-chip) assay showed that the lncRNA Mistral (MIRA) binds and recruits Mll1 to 
activate transcription of homeotic genes HOXA6 and HOXA7.113  When Hoxa6 and 
Hoxa7 are expressed, they are able to activate expression of germ layer marker genes to 
induced differentiation of murine embryonic stem cells (mESC).  Finally, work done by 
Paralker et al, used RNA sequencing in erythroblasts from both murine fetal liver and 
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human CD34+ cells derived from cord blood, identified 1109 and 594 polyadenylated 
lncRNAs, respectively.108  For both species, more than 50% of the lncRNAs were 
unannotated.  Data from mouse erythroblasts showed that the expression of many of these 
lncRNAs are regulated by Gata1 and Tal1, which are key erythroid-specific transcription 
factors; 15% of lncRNAs are expressed in human erythroblasts; and knockdown of 7 out 
of 21 of the most abundant lncRNAs inhibited terminal erythroid differentiation (6 of the 
7 were not expressed in human erythroblasts).  Only 15% of the lncRNAs in human 
erythroblasts were expressed in mouse erythroblasts, suggesting that lncRNAs expressed 
in erythroid cells are highly species-specific. 
1.5.3 Disease-associated lncRNAs 
LncRNAs have also been implicated as key players in disease pathophysiology, 
including Alzheimer’s disease, cancer and cardiovascular disease.114–119  β-secretase-1 
(BACE1)-AS is an antisense lncRNA transcribed complementary to the gene BACE1, 
which is known to be necessary for the formation of beta-amyloid and amyloid plagues 
found in patients with Alzheimer’s disease.120  Further investigation into the function of 
BACE1-AS discovered that this lncRNA actually interacts with and stabilizes the mRNA 
of BACE1, causing the upregulation of BACE1 protein levels.  This implies that BACE1-
AS is the key target to stop the production of amyloid plagues for treatment of 
Alzheimer’s disease.  In cancer, many lncRNAs have been found to be differentially 
expressed compared to their noncancerous counterparts.  MALAT1 is expressed in normal 
tissue; however, it is increased in multiple types of cancer.121–123  Functional analyses for 
MALAT1 show that when it is downregulated in cancer cells, they no longer have the 
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ability to proliferate, migrate and invade distal tissues.  In cardiovascular disease, SNPs 
found in lncRNAs such as ANRIL, have been found to be associated with myocardial 
infarction.124,125  Certain SNPs upregulated the expression of ANRIL, and promoted the 
production of peripheral blood mononuclear cells within the blood and buildup of 
atherosclerotic plagues within blood vessels, which can lead to a heart attack and stroke. 
LncRNAs are now considered important regulators of gene expression and 
processes of the cell, including erythroid cells.  Moreover, lncRNAs are implicated in 
disease pathophysiology that suggests the possibility that they might have some role in 
hemoglobinopathies such as SCD. 
1.6 Rationale and Hypothesis 
SCD is a genetic disease that affects the functions of both hemoglobin and RBCs.  
Not all individuals with SCD display the same disease phenotypes.  One factor known to 
affect the phenotype of disease is HbF.  The three known QTL only account for 20-45% 
of HbF variability.77,126,127  Therefore, more is to be discovered about the regulation of 
HbF. 
The HBS1L-MYB intergenic region is a key HbF-associated QTL.  Within this 
region is an enhancer element for MYB, which is known to regulate erythroid-specific 
traits.  Querying the ENCODE datasets in erythroid cells revealed the presence of a 50-bp 
RNA transcript from this enhancer element.  Knowing that enhancers can express 
functional lncRNAs, we hypothesized that this 50-bp RNA might be part of an eRNA 
transcribed from within the HBS1L-MYB intergenic region, specifically from the 
enhancer for MYB, and represents a putative lncRNA that regulates MYB and its 
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downstream targets.  If true, this might contribute to a better understanding of the 
regulation of erythropoiesis and hemoglobin expression, and this lncRNA could possibly 
be considered a therapeutic target for the treatment of SCD. 
1.7 Specific Aims 
There are two specific aims to address this hypothesis.  The first aim is to 
characterize the transcript by determining the following:  the full length, cellular location, 
relative expression compared to protein-coding genes, tissue-specificity, and the 
expression pattern among erythroid cells with different hemoglobin makeup and during 
erythroid differentiation.  The second aim is to address the functional aspect of the 
transcript, and determine if the transcript regulates MYB and hemoglobin gene 
expression.  
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CHAPTER 2.  CHARACTERIZATION OF THE TRANSCRIPT LOCATED 
WITHIN THE HBS1L-MYB INTERGENIC REGION 
2.1 Introduction 
Since the year 2000, when the International Human Genome Project made the 
assembly of the human genome available to the public, it became easier for investigators 
to know the location, length and sequence of genes of interest.128,129  However, the caveat 
to knowing these characteristics is that these genes would have to be annotated within the 
human genome assembly.  As scientific tools became more advanced, new genes were 
continuously added to the list.  RNA sequencing (RNA-Seq) is a tool used to profile the 
transcriptome by using next generation deep-sequencing technologies.130  The purpose of 
RNA-Seq is to determine which transcripts—mRNA, ncRNA and small RNA—are 
found, and quantify the amount of each individual transcript in a particular sample.  
However, there are still limitations, especially when it comes to characterizing lncRNAs 
due to the fact that they are expressed at very low levels compared to protein coding 
genes; and since lncRNAs are mostly tissue-specific, RNA has to be extracted from the 
right cell type. 
As discussed in Chapter 1, the 50-bp transcript found in the HBS1L-MYB 
intergenic region was discovered using ENCODE datasets from RNA-Seq analyses of 
K562 cells.  While it was plausible to consider this transcript a small noncoding RNA, we 
decided to perform additional analyses to determine if the outcome could possibly be 
different.  RNA-Seq of RNA derived from primary erythroblasts showed multiple reads 
from this same region. 
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2.2 Determining the Full Length of the Transcript 
The first set of experiments done to address the question of whether the 50-bp 
transcript was part of a lncRNA, used reverse transcription polymerase chain reactions 
(RT-PCRs).  First, multiple primers were developed consecutively downstream and 
upstream the genomic region of the 50-bp transcript, at 100-bp intervals, spanning a 1400 
bp region.  We used for PCR complementary DNA (cDNA) (DNA synthesized from 
RNA) of K562 cells, which are immortalized erythroid cells that can be induced to make 
HbF.  The controls used for PCR were PCR mix without DNA input (negative control), 
PCR mix with genomic DNA (positive control), and PCR mix with cDNA generated 
without reverse transcriptase (negative control to ensure RNA was not contaminated with 
DNA).  The PCR reactions were done with primers starting from the 50-bp region and 
extended further with the next consecutive primers until there was no amplification.  The 
longest PCR product amplified was 1180 bp (chr6: 135096355-135097534; UCSC 
Genome Browser assembly ID:  hg38) (Figure 2.1A), and therefore upheld our 
hypothesis that a lncRNA was expressed from the HBS1L-MYB intergenic region. 
We next determined the entire length of the lncRNA by using rapid amplification 
of cDNA ends (RACE).  RACE is used to determine the 5’- and 3’-ends of full length 
RNA by ligating adapters to ends of cDNA, and then amplifying the transcript of interest 
with adapter-specific and gene-specific primers.131  After confirmation of a PCR product 
by running the reaction on an agarose gel, the product is purified, cloned into a vector, 
and analyzed further to determine the exact location of the ends of the RNA (see 
subsection 2.8.6).  Most RACE protocols use cDNA as the starting material, which can 
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produce non-specific amplification (especially for the 5’-end reactions) due to the lack of 
selectivity of specific RNAs.  However, improvements have been made to produce a 
single band after PCR.  Therefore, RNA Ligase Mediated (RLM) RACE was used, 
which, for the 5’-end, used RNA as the starting material; removed all degraded RNA, 
rRNA, tRNA and DNA; removed the 5’-cap (leaving only a monophosphate); ligated an 
adapter (will only ligate to RNA with the 5’-monophosphate); reverse transcribed RNA; 
and amplified 5’-end with adapter-specific and gene-specific primers.  The RLM-RACE 
protocol for the 3’-end has fewer steps and higher success rate than the 5’-RACE.  To 
determine the 3’-end, total RNA is reverse transcribed, adapter is ligated to 3’-end, and 
then PCR reactions are done with adapter-specific and gene-specific primers.  RNA from 
K562 cells was initially used for both 5’- and 3’-RACE, however there was a huge DNA 
smear for the 5’-RACE, which could not be cloned into a vector for further analysis.  The 
sequencing results for the 3’-RACE of K562 cells revealed that the 3’-end of the lncRNA 
was at location ch6: 135097644 (hg38) (Supplemental Figure 3), which was 110 bp 
downstream from what was found by RT-PCR (Figure 2.1B).  As for the 5’-RACE, it 
was repeated using RNA from erythroblasts derived from cord blood CD34+ cells.  This 
time there were multiple bands, and each band was cloned and analyzed further, however, 
none of the sequencing results were found to be from this region.  During the analysis of 
the expression pattern of this lncRNA among various types of tissues, it was found that 
the thymus expressed the lncRNA at much higher levels than both K562 cells and CD34+ 
cells (see section 2.3).  Repeating 5’ RLM-RACE using RNA from the thymus showed 
only one band.  Sequencing results of that band revealed that the 5’-end of this lncRNA 
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was at location ch6: 135096362 (hg38) (Supplemental Figure 4 and Figure 2.1B).  
HUDEP-2 cells, another immortalized erythroid cell line that expresses HbA, expressed 
more of the transcript than both K562 cells and erythroblasts derived from CD34+ cells.  
Both the 5’ and 3’ RLM-RACE analyses gave the same results in these cells.  The full 
length of this lncRNA, which we named the HBS1L-MYB intergenic long noncoding 
RNA (HMI-LNCRNA), is 1283 bp at chr6: 13509362-135097644 (hg38) (Figure 2.1C).  
HMI-LNCRNA is located 84.9 kb upstream from MYB and 41.5 kb upstream from 
HBS1L, and includes binding sites for erythroid transcript factors TAL1/E47, GATA1 
and RUNX1, HbF-associated polymorphism rs66650371, and is transcribed from the 
enhancer for MYB.  There is also no evidence of protein coding potential of HMI-
LNCRNA based on the fact that it is absent in protein databases and contains no open 
reading frames longer than 300 nucleotides. 
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Figure 2.1.  Determining the full length of the transcript found within the HBS1L-
MYB intergenic region. 
(A) PCR was done to amplify a 1180 bp region within the HBS1L-MYB intergenic region 
using cDNA from K652 cells.  Samples were run on agarose gels and exposed under UV 
light.  Lane 1:  100-bp DNA ladder; lane 2:  negative control, PCR mix without DNA 
input; lane 3:  positive control, PCR mix with genomic DNA; lane 4:  PCR mix with 
cDNA generated without reverse transcriptase; and Lane 5:  PCR mix with cDNA 
generated with reverse transcriptase.  (B) Agarose gels show PCR products from the 5’-
RACE reactions (using RNA from thymus) and 3’-RACE reactions (using RNA from 
K562 cells).  For 5’-RACE, lane 1:  100-bp DNA ladder; lane 2:  PCR mix with cDNA 
generated without Tobacco Acid Pyrophosphatase (TAP) treatment; and lane 3:  PCR 
mix with cDNA generated with TAP treatment.  For 3’-RACE, lane 1:  100-bp DNA 
ladder; lane 2:  PCR mix with cDNA generated without reverse transcriptase; and lane 3:  
PCR mix with cDNA generated with reverse transcriptase.  (C) Illustration of genomic 
region between 134950000-135250000 (hg38 coordinates) of chromosome 6, showing 
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approximate locations of rs66650371 and rs9399137, and HBS1L and MYB (arrows 
represent transcription direction and approximate length of genes).  Based on DNA 
sequencing of RACE products, the 5’- and 3’-ends of the transcript were revealed to 
determine the full length of the transcript, which is 1283 bp in length and named the 
HBS1L-MYB Intergenic Long Noncoding RNA (HMI-LNCRNA).  Located in the 
genomic sequence for HMI-LNCRNA are binding sites for erythroid-specific transcription 
factors TAL1/E47, GATA and RUNX1, and the 3-bp polymorphism (rs66650371).  
HMI-LNCRNA does not include rs9399137. 
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2.3 Tissue Specificity of HMI-LNCRNA 
Since lncRNAs are expressed in either one or a few tissue types (more tissue-
specific than mRNA), we explored the expression pattern of HMI-LNCRNA among 25 
different types of cells and tissues.  RNA samples were either purchased or extracted, and 
HMI-LNCRNA expression was analyzed by quantitative PCR (qPCR).  Not all tissue 
expressed HMI-LNCRNA.  The fold change of expression by qPCR in multiple samples 
that included erythroblasts derived from cord blood CD34+ cells, bone marrow, fetal 
liver, brain, spleen, skeletal muscle, spinal cord, testis and thymus, had expression level 
of at least 1-fold above K562 cells; only three samples (erythroblasts derived from cord 
blood CD34+ cells, testis and thymus) had a fold change above 10; and only one sample 
(thymus) had a fold change above 1000 (Figure 2.2).  T-cells found in the thymus and 
erythroid cells both are derived from hematopoietic stem cells (HSCs), and require MYB 
to regulate differentiation.  MYB is low in both mature erythroid cells and mature T-
cells.27  This suggests that HMI-LNCRNA may work together with MYB to regulate 
differentiation of both cell types.  If this is so, we might expect higher levels of HMI-
LNCRNA in HSCs, and declining levels during the maturation of each cell type.  
However, it is unknown if the expression of HMI-LNCRNA in the thymus is from the T-
cells, their precursors or a non-associated cell type.  HMI-LNCRNA in peripheral blood 
mononuclear cells (PBMCs), which consists of 40-70% mature T-cells, was low, 
suggesting that the high levels of this lncRNA maybe coming from T-cell precursors. 
The expression pattern of MYB in these same samples was evaluated to determine 
if it correlated with the expression pattern of HMI-LNCRNA.  K562 cells, which express 
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very low levels of HMI-LNCRNA compared to erythroblasts derived from cord blood 
CD34+ cells and the thymus, had the highest expression of MYB among all the samples 
tested (Supplemental Figure 1).  However, MYB has 13 isoforms, and the primer used 
for qPCR only recognizes one isoform.  If different isoforms for MYB were expressed 
among these samples, primers specific to the isoform expressed in each sample would be 
needed to evaluate MYB expression. 
2.4 Cellular Location of HMI-LNCRNA 
Unlike mRNAs, which translocate to the cytoplasm to undergo translation, 
lncRNAs can either stay in the nucleus or move to the cytoplasm after transcription, 
depending on their function.  Most lncRNAs are located in the nucleus because they 
regulate gene expression.  Hence, it was important to know if HMI-LNCRNA is expressed 
in the nucleus or the cytoplasm.  Primary erythroblasts derived from cord blood CD34+ 
mononuclear cells were harvested and underwent nuclear and cytoplasmic fractionation.  
RNA was extracted from each fraction, and the relative transcript level of HMI-LNCRNA 
was analyzed by qPCR.  HMI-LNCRNA was expressed almost entirely in the nucleus 
(Figure 2.3), suggesting that HMI-LNCRNA regulates gene expression.  Regulation could 
affect MYB, HBS1L or another protein-coding gene. 
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Figure 2.2.  Expression pattern of HMI-LNCRNA among various human cells and 
tissue. 
Relative quantity of HMI-LNCRNA was measured by qPCR in 25 different samples.  
CD34+ cord blood day 11 is erythroblasts harvested at Day 11 of two-phase expansion 
and differentiation culture of CD34+ mononuclear cells derived from cord blood.  Means 
are shown for samples with two or more independent samples.  ACTB was used as the 
endogenous control. 
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Figure 2.3.  HMI-LNCRNA expression in nuclear and cytoplasmic fractions of 
primary erythroid cells derived from cord blood CD34+ mononuclear cells. 
Nuclear and cytoplasmic fractions were extracted from erythroid cells derived from cord 
blood CD34+ mononuclear cells at Day 8 (n=1) and Day 12 (n=2) of differentiation.  
RNA extracted from each fraction was analyzed by qPCR analysis for expression of 
HMI-LNCRNA.  The ratio of the relative quantity of nuclear to cytoplasmic HMI-
LNCRNA transcripts was measured.  ACTB was used as the endogenous control.  p-value:  
***<0.005.  p-value obtained by Student T-test. 
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2.5 Comparing the Relative Expression Level of HMI-LNCRNA to a Protein-Coding 
Gene 
LncRNAs have been shown to be less abundant than mRNA from protein-coding 
genes.  To determine if HMI-LNCRNA shares this same characteristic, the relative 
expression level of HMI-LNCRNA was compared to the expression of MYB by qPCR.  
Using RNA extracted from HUDEP-2 cells and erythroblasts derived from peripheral 
blood CD34+ cells, MYB was expressed 300 to 500 times more than HMI-LNCRNA 
(Figure 2.4). 
               
Figure 2.4.  Ratio of MYB to HMI-LNCRNA expression in HUDEP-2 cells and 
erythroid cells derived from peripheral blood CD34+ mononuclear cells. 
Relative quantity ratio of MYB to HMI-LNCRNA was determined in HUDEP-2 cells 
(n=2) and erythroid cells derived from primary peripheral blood mononuclear cells at 
Day 9 of differentiation (n=3) by qPCR.  ACTB was used as the endogenous control. 
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2.6 Relative Expression Pattern of HMI-LNCRNA Between Erythroid Cells with 
Different Hemoglobin Phenotypes and During Erythroid Differentiation 
MYB is known to be associated with low HBG and high HBB expression.  We 
therefore sought to determine if HMI-LNCRNA was associated with the expression of 
fetal or adult globin genes.  HMI-LNCRNA and MYB mRNA expression were compared 
in fetal-like erythroid cells expressing HBG and adult-like cells expressing HBB.  The 
first set of cells analyzed were HUDEP-1 cells, which express 99% HBG and HUDEP-2 
cells, which express 99% HBB.  HMI-LNCRNA was significantly higher in HUDEP-2 
cells compared to HUDEP-1 cells, however, there was no difference in expression of 
MYB (Figure 2.5A).  The results for MYB do not mirror protein expression of c-MYB, 
which was found to be higher in HUDEP-2 cells compared to HUDEP-1 cells (see 
Chapter 3, subsection 3.2.4).  This suggested that even though there may not be a 
difference transcriptionally, there could be differences in the translation of MYB mRNA, 
or degradation and/or stability of c-MYB between HUDEP-1 and HUDEP-2 cells.  In 
primary erythroblasts derived from cord blood CD34+ cells that express 95% HBG and 
peripheral blood CD34+ cells that express 65% HBG, both HMI-LNCRNA and MYB were 
significantly higher in erythroblasts derived from peripheral blood compared to cells 
derived from cord blood (Figure 2.5B).  These data suggest that high levels of MYB and 
HMI-LNCRNA expression are associated with increased HBB expression and reduced 
HBG expression. 
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Figure 2.5.  HMI-LNCRNA and MYB expression pattern in HUDEP-1 and HUDEP-
2 cells, and erythroid cells derived from cord blood and peripheral blood CD34+ 
mononuclear cells. 
(A) Percent HBG to HBB, and the relative quantity of HMI-LNCRNA and MYB were 
determined by qPCR analysis in HUDEP-1 (n=3) and HUDEP-2 (n=2) cells (both 
maintained in expansion medium).  (B) Primary erythroid cells derived from cord blood 
(n=3) and peripheral blood (n=3) CD34+ mononuclear cells (both expanded for 7 days 
and differentiated for 2 days) were analyzed by qPCR analysis to determine percent HBG 
to HBB, and the relative quantity of MYB and HMI-LNCRNA.  ACTB was used as the 
endogenous control.  p-values:  *< 0.05; **< 0.005; ***<0.0005; NS (not significant).  p-
values were obtained by Student T-test. 
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Another characteristic of lncRNAs is that they are differentially expressed during 
development.  Therefore, since HMI-LNCRNA is associated with erythroid cells that 
express more HBB, the expression pattern of this lncRNA was analyzed during 
differentiation of HUDEP-2 cells and peripheral blood CD34+ mononuclear cells.  During 
the differentiation of both cell types, HMI-LNCRNA and MYB mRNA decreased (Figure 
2.6). 
Taken together, these data show that both HMI-LNCRNA and MYB have similar 
expression patterns in erythroid cells, and suggest that HMI-LNCRNA may regulate the 
transcription of MYB. 
    
Figure 2.6.  HMI-LNCRNA and MYB expression pattern during differentiation of 
HUDEP-2 cells and erythroid cells derived from peripheral blood CD34+ 
mononuclear cells. 
(A) Fold change of HMI-LNCRNA and MYB were determined in HUDEP-2 cells at Days 
0, 5 and 7 in cultures with differentiation medium.  (B) Fold change of HMI-LNCRNA 
and MYB were determined during differentiation of CD34+ mononuclear cells derived 
from adult peripheral blood (n=3) at Days 7, 9, 11, 13 and 15.  ACTB was used as the 
endogenous control.  p-values:  *< 0.05; **< 0.005; ***<0.0005; NS (not significant).  p-
values were obtained by Student T-test. 
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2.7 Summary and Conclusions 
The 50-bp transcript annotated by ENCODE and located within the HBS1L-MYB 
intergenic region, which is known to regulate erythroid-specific traits, became an 
interesting element in our mission to better understand hemoglobin regulation.  
Therefore, additional steps were taken to fully characterize this transcript.  The first step 
was to determine the full length of this transcript.  By RT-PCR, and 5’- and 3’-RACE, we 
discovered that the transcript is 1283 bp (chr 6:  135096362-135097644, hg38) and is a 
lncRNA; it contains the binding sites for erythroid-specific transcription factors; and it is 
transcribed from the enhancer region of MYB, which brands it an enhancer RNA (eRNA). 
This lncRNA was named the HBS1L-MYB intergenic region long noncoding RNA (HMI-
LNCRNA).  HMI-LNCRNA is not erythroid-specific, however, it was expressed in only a 
few cell/tissue types and could possibly be hematopoietic-specific.  The expression 
pattern of HMI-LNCRNA in erythroid cells was mostly nuclear; it was less abundant than 
MYB mRNA; higher expression was associated with erythroid cells that express more 
HBB; and it was downregulated during erythroid differentiation.  HMI-LNCRNA and 
MYB showed the same expression pattern in erythroid cells and during erythroid 
differentiation (Figure 2.7). 
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Figure 2.7.  Summary of the characteristics of HMI-LNCRNA. 
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2.8 Materials and Methods 
2.8.1 K562 cells 
K562 cells are immortalized erythroid progenitors derived from pleural effusion 
of a patient with chronic myelogenous leukemia.  They can be differentiated with 
arginine butyrate treatment toward erythroblasts that express only embryonic and fetal 
hemoglobin (Supplemental Figure 2.4).132  They were cultured at 37 degrees Celsius 
(°C) in RPMI medium containing 10% FBS and 2% penicillin/streptomycin.  To induce 
hemoglobin expression, cells are seeded at a concentration of 1x105 cells/ml with 1 mM 
arginine butyrate, and cultured at 37°C for seven days (medium changed every two days). 
2.8.2 HUDEP cells 
Human umbilical cord blood-derived erythroid progenitor (HUDEP) cells are an 
immortalized erythroid cell lines derived from cord blood CD34+ mononuclear cells.133  
HUDEP-1 and HUDEP-2 cells were cultured at 37°C maintained in StemSpan SFEM 
medium (StemCell Technologies) supplemented with SCF (50 ng/ml, Invitrogen), EPO 
(3 U/ml, Invitrogen), dexamethasone (1 µM, Sigma), doxycycline (1 µg/ml, Clontech), L-
glutamine (1%, Life Technologies) and penicillin/streptomycin (2%, Life Technologies).  
For erythroid maturation, cells were cultured at 37°C in IMDM medium (Invitrogen) 
supplemented with heat inactivated human serum from human male AB plasma (5%, 
Sigma), EPO (3 U/ml, Invitrogen), insulin (10 µg/ml, Sigma), doxycycline (1 µg/ml, 
Clontech), holo-transferrin (500 µg/ml, Sigma), heparin (3 U/ml, Sigma), SCF (100 
ng/ml, Invitrogen), L-glutamine (1%, Life Technologies) and penicillin/streptomycin 
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(2%, Life Technologies) for 5 days.  For further erythroid maturation, doxycycline was 
removed and cells were cultured for two more days. 
2.8.3 Primary CD34+ mononuclear cells 
Primary CD34+ mononuclear cells derived from cord blood and peripheral blood 
(StemCell Technologies) contain hematopoietic stem/progenitor cells that can be 
differentiated into multiple lineage-specific cells.  To generate erythroid cells, CD34+ 
cells underwent a 2-phase culture system.  The first phase is to expand the cells at 37°C 
in StemSpan SFEM II medium (StemCell Technologies) supplemented with StemSpan 
CC100 (1X, StemCell Technologies) and penicillin/streptomycin (2%, Life 
Technologies) for six or seven days.  The second phase is to drive the cells to erythroid 
lineage.  To induce erythroid differentiation, cells were cultured at 37°C in StemSpan 
SFEM II medium (StemCell Technologies) supplemented with SCF (10 ng/ml, 
Invitrogen), EPO (5 U/ml, Invitrogen), IL-6 (10 ng/ml, Sigma) and 
penicillin/streptomycin (2%, Life Technologies) for up to 10 days (Supplemental Figure 
2). 
2.8.4 RNA extraction 
Cells taken from culture were centrifuged at 300 x g for 10 minutes at 4°C.  Next, 
supernatant was removed without disturbing cell pellet, cells were resuspended in cold 
1X Phosphate-buffered saline (PBS) and centrifuged again at 300 x g for 10 minutes at 
4°C.  After removal of supernatant, cell pellets were stored at -80°C or processed for 
RNA extraction.  Total RNA was extracted using RNeasy Mini Kit (Qiagen), treated with 
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DNase (RNase-Free DNase Set, Qiagen), and then purified by RNA cleanup using 
RNeasy Mini Kit.  For tissue-specificity experiment, multiple human organ RNA panels 
(Invitrogen and Clontech) were treated with DNase, followed by RNA cleanup. 
DNase treatment is necessary for qPCR analysis for HMI-LNCRNA.  In my earlier 
experiments, there was non-specific amplification in reactions without reverse 
transcriptase, which suggest that the reaction was contaminated with DNA.  However, the 
non-specificity was only a problem when I used the primer for HMI-LNCRNA, and not 
for the other primers, such as ACTB and HBG, which had no amplification in qPCR 
reactions without reverse transcriptase.  I have heard from other investigators that this is 
problem when analyzing lncRNAs by qPCR, but they do not understand why this occurs.  
I tried multiple DNase treatment protocols, such as incubating the column with DNase 
before eluting the RNA, however there was still non-specific amplification.  What did 
work is after extracting the total RNA, incubate the entire sample in DNase for 10 
minutes, and then cleanup the RNA to remove the DNase and buffer. 
2.8.5 Reverse transcription polymerase chain reaction (RT-PCR) 
cDNA was synthesized from DNase-treated RNA using SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen).  Oligo(dT)20 was used for the 
annealing step, therefore, cDNA was synthesized from only poly(A)+ RNAs. 
PCR reactions were done using the Multiplex PCR kit (Qiagen).  The following 
primers were used to amplify the 1180 bp product:  5’-ATCGCTCATGAGAAATGTGG-
3’ (forward) and 5’-GGAACCGCCCTGATAACATT-3’ (reverse). 
  
47 
2.8.6 Rapid amplification of cDNA ends (RACE) 
5’- and 3’-RACE were done using the FirstChoice RLM-RACE Kit (Ambion), 
following the manufacturer’s instructions, using SuperTaq Plus Polymerase (Life 
Technologies) for PCR reactions.  For 5’-RACE, the negative control was cDNA 
synthesized from RNA that was not treated with Tobacco Acid Pyrophosphatase (TAP).  
TAP removes the 5’-cap from RNA and leaves only a monophosphate.  After TAP 
treatment, the adapter is ligated to only RNA with the monophosphate at the 5’-end.  
Therefore, RNAs not treated with TAP cannot ligate to the adapter, and will not amplify 
during the PCR reactions because the primer specific for the adapter cannot bind to them.  
The following gene-specific primers were used:  5’-
GTCTAATGGTGTGGCTCACAAA-3’ (5’-outer), 5’-
CCCCAGCTTCCTTATCTGTAAA-3’ (5’-inner), 5’-
TTCACTCTGGACAGCAGATGTT-3’ (3’-outer) and 5’-
CGGTTCCCTCAGAAGACACTTA-3’ (3’-inner).  RACE PCR products were ligated to 
pCRII vector using TA Cloning Dual Promoter Kit (Invitrogen), transformed into One 
Shot INVαF chemically competent E. coli (Invitrogen), and grown on LB plates 
containing 100 µg/ml ampicillin and X-Gal.  Insert-positive white colonies were picked 
and grown for DNA extraction.  PCR reactions were done to amplify the regions where 
the RACE products were ligated to the vector (Forward: 5’-
TGTGGAATTGTGAGCGGATA-3’ and Reverse: 5’-GTTTTCCCAGTCACGACGTT-
3’), and then processed for DNA sequencing. 
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2.8.7 DNA sequencing 
PCR products were purified using AccuPrep PCR Purification Kit, and prepared 
for sequencing using ABI Big Dye Terminator v3.1 Cycle Sequencing Kit, which uses 
only one primer (forward or reverse) that was previously used for PCR.  The program 
used for PCR was based on the DNA sample.  If sequencing genomic DNA or cDNA, the 
following program was used:  96°C for 1 min; 15 cycles (96°C for 10 sec, 50°C for 5 sec, 
60°C for 1 min 15 sec; 5 cycles (96°C for 10 sec, 50°C for 5 sec, 60°C for 1 min 30 sec); 
5 cycles (96°C for 10 sec, 50°C for 5 sec, 60°C for 2 min); 10°C hold.  If sequencing 
plasmid DNA, the following program was used:  96°C for 1min; 25 cycles (96°C for 10 
sec, 50°C for 5 min, 60°C for 4 min); 4°C hold.  ABI 3130xl Genetic Analyzer was used 
for sequencing.  Sequence data was analyzed on FinchTV version 1.5.0.  NCBI BLAST 
was used to determine location of sequence. 
2.8.8 Nuclear and cytoplasmic fractionation 
Cells taken from culture were centrifuged at 300 x g for 10 minutes at 4°C.  Next, 
supernatant was removed without disturbing cell pellet, cells were resuspended in cold 
1X Phosphate-buffered saline (PBS) and centrifuged again at 300 x g for 10 minutes at 
4°C.  After removal of supernatant, cells were processed using the Nuclear/Cytosol 
Fractionation Kit (BioVision), following manufacturer’s instructions. 
2.8.9 Quantitative PCR 
qPCR—also known as real-time PCR—is a tool used to quantitate the relative 
transcript levels of a specific RNA.  In the PCR phase, gene-specific primers are used to 
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amplify the target during a 40-cycle reaction period (1-40).  More abundant transcripts 
are amplified at earlier cycle thresholds (Ct) values, while less abundant transcripts are 
amplified at later Ct values.  To calculate the relative quantity of a transcript-of-interest 
(TOI), first take the difference between Ct of TOI and Ct of endogenous control, such as 
ACTB (β-actin), to get ΔCt (CtTOI – CtACTB = ΔCtTOI).  Finally, the relative quantity of 
TOI is calculated using 2(-(ΔCt)).  To calculate fold change between two samples—sample 
1 (S1) and sample 2 (S2)—another approach is taken.  For each sample, calculate ΔCtTOI.  
Next, calculate ΔΔCtTOI for each sample—for S1, [(ΔCtTOI for S1) – (ΔCtTOI for S1)] = 
(ΔΔCtTOI for S1) = 0; and for S2, [(ΔCtTOI for S2) – (ΔCtTOI for S1)] = (ΔΔCtTOI for S2).  
Last, the fold change of the TOI for each sample is calculated using 2(-(ΔΔCt)), in which S1 
will equal 1. 
Total RNA, TaqMan primers and reagents from the TaqMan RNA-to-CT 1-Step 
Kit (Applied Biosystems) were the components used to make 20 µl reaction mix for each 
sample (done in triplicate) that was loaded onto a 96-well plate, following manufacturer’s 
instructions.  The following TaqMan gene expression assays (Applied Biosystems) were 
used:  HBG1/2 (Hs00361131_g1), HBB (Hs00758889_s1), MYB (Hs00920556_m1), 
HMI-LNCRNA (custom TaqMan assay designed by Applied Biosystems to target genome 
position chr6: 135096354-135097644, hg38; assay ID number AJI1MTQ), and ACTB 
(Hs01060665_g1).  QPCR reactions were ran on a StepOne Plus qPCR machine (Applied 
Biosystems).  ACTB was used as the endogenous control. 
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CHAPTER 3.  THE EFFECTS OF MODULATING HMI-LNCRNA EXPRESSION 
IN ERYTHROID CELLS 
3.1 Introduction 
Characterization of HMI-LNCRNA has given insight into how this lncRNA 
possibly functions in erythroid cells, possibly as an eRNA that promotes the expression 
of MYB, thereby regulating hemoglobin expression, and erythroid proliferation and 
maturation.  To determine if HMI-LNCRNA regulated MYB and erythroid-specific traits, 
we employed various systems to modulate its expression in erythroid cells. 
There are multiple techniques used to either knockdown or overexpress RNAs in 
vitro.  To downregulate expression of RNAs, small interference RNAs (siRNAs), locked 
nucleic acids (LNAs) and short hairpin RNAs (shRNAs) can be used.  siRNAs are 
synthetically made double-stranded RNAs (dsRNAs) of 20-25 nucleotides that are 
complementary to the RNA of interest.  Cells are transfected with siRNAs using various 
methods that will allow the siRNAs to travel through the cell membrane and into the 
cytoplasm.  Once in the cytoplasm, siRNAs are processed by Dicer to separate the two 
strands, and then binds to the RNA-induced silencing complex (RISC).  The siRNA-
RISC complex binds to the RNA of interest and cleaves it, reducing the amount of RNA 
in the cell.  LNAs are a newer system that uses RNase H to cut the RNA of interest.134  
Cells are treated with a single-stranded RNase H activating DNA flanked by antisense 
oligonucleotides specific to the RNA of interest, and require no transfection reagent.  
After the LNA is in the cell, the antisense oligonucleotides binds to the RNA of interest 
and the RNase H activating DNA recruits RNase H to cut the RNA.  Similar to siRNAs, 
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shRNAs use Dicer to separate the double-stranded DNA, and RISC to cleave RNA.  
However, they differ in the way they are made and introduced to the cell.  An shRNA is a 
synthetically made double-stranded DNA template containing four specific regions—
sense, loop, antisense and terminator.  The sense region is about 20 bp of the genomic 
region where the RNA of interest is transcribed from; the loop is 10 bp of nonsense 
nucleotides; antisense is complementary to the sense; and the terminator consists of 
nucleotides that will stop transcription.  The shRNA template is ligated to a lentivector, 
which contains virus-specific genes that allow for efficient cell transduction and genome 
integration.  Once integrated into the genome, shRNA is expressed, forms into a hairpin 
structure and undergoes the same processing as siRNAs. 
There are also methods to completely stop transcription of RNAs.  Gene editing 
uses nucleases such as zinc finger nucleases (ZFNs), transcription-activator like effector 
nucleases (TALENs) and clustered regularly interspaced short palindromic repeats 
(CRISPR) to edit the genome to inhibit gene transcription.  One caveat to using gene 
editing, especially when studying intergenic lncRNAs, is that genomic regions with 
epigenetic regulatory elements such as enhancers and promoters cannot be targeted.  The 
effects observed maybe due to the lack of such elements, not the lack of transcription of 
the lncRNA of interest. 
The decision in determining which system to use to knockdown HMI-LNCRNA 
was based on one key characteristic—its expression is almost entirely in the nucleus.  
siRNAs will not be effective as they stay in the cytoplasm.  Therefore, shRNAs were 
used due to the fact that they integrate into the genome, and therefore are expressed in the 
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nucleus.  Overexpressing HMI-LNCRNA also required its expression in the nucleus.  
Hence, full length HMI-LNCRNA was cloned into a lentivirus and used to transduce 
erythroid cells. 
3.2 Downregulation of HMI-LNCRNA in erythroid cells 
3.2.1 Determining which shRNA most effectively reduces expression of HMI-LNCRNA 
Three different shRNA templates (HMIT-1, HMIT-2 and HMIT-3) were 
developed to target HMI-LNCRNA, and cloned into the pGreenPuro lentivector.  
pGreenPuro is an HIV-based expression lentivector, and contains multiple components 
for cloning, lentiviral production and transduction, and shRNA expression (see 
subsection 3.5.1 for details).  pGreenPuro also expresses green fluorescent protein (GFP), 
which can be detected by flow cytometry to determine the percentage of cells infected 
with lentivirus.  To determine which shRNA template most efficiently downregulates 
HMI-LNCRNA, each shRNA plasmid was transduced into TF-1a cells and cultured in 
puromycin for up to two weeks to select for only cells infected with lentivirus.  At the 
time cells were harvested for analysis for expression of HMI-LNCRNA, about 95% of the 
cells were GFP-positive (GFP+).  HMI-LNCRNA was reduced with all shRNA templates, 
with HMIT-1 showing the greatest reduction at 70% (Supplemental Figure 3.1).  This 
experiment was repeated in HUDEP-2 cells, however the cells were analyzed two days 
after transduction without puromycin treatment.  When cells were harvested, about 30% 
were GFP+, and a significant decrease in HMI-LNCRNA was found only in cells 
transduced with HMIT-1 (Supplemental Figure 3.2).  Based on the observations from 
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qPCR analysis for HMI-LNCRNA, HMIT-1 shRNA was used for all knockdown 
experiments, and was labeled as HMI-lncRNA shRNA. 
3.2.2 Downregulation of HMI-LNCRNA in HUDEP-1 and HUDEP-2 cells 
HUDEP-1 and HUDEP-2 cells were used for knockdown of HMI-LNCRNA 
expression.  Each cell line was split into three groups—naïve (non-transduced), 
scrambled shRNA and HMI-lncRNA shRNA.  Each group had three biological 
replicates.  Two weeks after the second transduction, cells were collected for the 
following analyses:  flow cytometry for GFP; qPCR for HMI-LNCRNA, HBS1L, MYB, 
HBG, HBB, and ACTB; Western blot analysis for HBG, HBB, c-MYB; and slide 
preparations for immunofluorescent staining for HBG and HBB (Figure 3.1A).  The first 
two experiments that were done to ensure that almost all cells were infected and that 
HMI-LNCRNA was significantly downregulated, and therefore used flow cytometry for 
GFP and qPCR for HMI-LNCRNA, respectively.   
Flow cytometry results in HUDEP-2 cells showed that there were no GFP+ cells 
in the naïve group, 84% GFP+ in the scrambled shRNA group and 90% GFP+ cells in the 
HMI-lncRNA shRNA group (Supplemental Figure 3.3).  qPCR results for HMI-
LNCRNA showed there was about 50% reduction in the HMI-lncRNA group compared to 
both naïve and scrambled shRNA groups (Figure 3.1B).  Almost the entire cell 
population of HUDEP-2 cells transduced with either scrambled shRNA or HMI-lncRNA 
shRNA was infected, and there was a significant reduction in of HMI-LNCRNA.  
Transduction of HUDEP-2 cells was repeated but with the addition of allowing the cells 
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to mature.  Both GFP-positivity and reduction of HMI-LNCRNA was similar to the first 
experiment. 
 
Figure 3.1.  Downregulation of HMI-LNCRNA in HUDEP-2 cells. 
(A) Illustration of timeline for transduction and culture of HUDEP-2 cells.  Cells were 
maintained in expansion medium.  (B) Expression level of HMI-LNCRNA was 
determined by qPCR in HUDEP-2 cells that were not transduced (naïve), and transduced 
with either scramble shRNA or HMI-lncRNA shRNA lentiviruses by qPCR.  ACTB was 
used as the endogenous control.  p-values:  *< 0.05; **< 0.005; ***<0.0005; NS (not 
significant).  p-values were obtained by Student T-test. 
 
  
  
55 
In HUDEP-1 cells, no GFP+ cells were found in the naïve control group, 89% 
GFP+ cells were found in the scrambled shRNA group and 92% GFP+ cells were present 
in the HMI-lncRNA shRNA group (Supplemental Figure 3.4A).  This result showed 
that almost all cells that were transduced expressed the shRNAs.  However, there was no 
change in HMI-LNCRNA expression (Supplemental Figure 3.4B).  This was probably 
due to the fact that these cells expressed relatively low levels of HMI-LNCRNA compared 
with HUDEP-2 cells, reducing any effect of shRNA knockdown.  In further experiments, 
knockdown of HMI-LNCRNA was only done in HUDEP-2 cells. 
3.2.3 The effect of knocking down HMI-LNCRNA on the expression of HBS1L and MYB 
Since HBS1L and MYB are the two genes in proximity to HMI-LNCRNA, the 
mRNA levels of both genes in HUDEP-2 cells infected with HMI-lncRNA shRNA was 
assessed.  qPCR analysis showed that there was no change in HBS1L and a significant 
30% reduction in MYB compared with HUDEP-2 cells transduced with scrambled 
shRNA control, and this was also reflected in the protein level of c-MYB (Figures 3.2A 
and 3.3A).  This change in MYB expression was reflected in one of two experiments.  
Pending additional studies, the regulation of MYB by HMI-LNCRNA is inconclusive. 
3.2.4 Effects of knocking down HMI-LNCRNA on the expression of HBG and HBB 
The expression pattern of both HBG and HBB among the naïve, scrambled 
shRNA and HMI-lncRNA shRNA groups were investigated by qPCR.  Knocking down 
HMI-LNCRNA had no effect on HBB expression in one experiment and a 4-fold increase 
in expression in the second experiment.  In contrast, there was a 200-fold increase in 
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HBG mRNA in HUDEP-2 cells transduced with HMI-lncRNA shRNA compared to both 
naïve and scrambled shRNA controls (Figure 3.2A).  The percent HBG increased from 
less than 1% in naïve and scramble shRNA cells to more than 20% of the total HBG and 
HBB expression in cells with HMI-lncRNA shRNA (Figure 3.2B).  Modulation of γ-
globin expression was also seen at the protein level, with detectable HBG expression only 
found in cells with knockdown of HMI-LNCRNA (Figure 3.3B).  These results were 
corroborated with immunofluorescent staining using anti-HBG antibody tagged with a 
secondary red fluorescent antibody.  The high HBG expression appeared to be restricted 
to a small subpopulation of HUDEP-2 cells with knockdown of HMI-LNCRNA.  There 
was no difference in protein levels of HBA and HBB between the three groups 
(Supplemental Figure 3.5).  In another experiment, HBG mRNA was also significantly 
elevated 900-fold with knockdown of HMI-LNCRNA compared with naïve and scrambled 
shRNA controls, with about 20% HBG of total HBG and HBB mRNA.  This effect was 
also present at the protein level. 
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Figure 3.2.  The effects of knocking down HMI-LNCRNA on the expression of HBG, 
HBB, MYB and HBS1L in HUDEP-2 cells. 
(A) HBG, HBB, MYB and HBS1L transcript levels, and (B) percent HBG and HBB out of 
the total of both transcripts were measured in these same samples For qPCR analyses, 
ACTB was used as the endogenous control.  p-values:  *< 0.05; **< 0.005; ***<0.0005; 
NS (not significant).  p-values were obtained by Student T-test. 
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Figure 3.3.  The effects of knocking down HMI-LNCRNA on the protein expression 
of c-MYB, HBG and HBB. 
(A) Protein expression of c-MYB, HBG and HBB were analyzed by Western blot in 
naïve HUDEP-2 cells, and cells transduced with scrambled shRNA and HMI-lncRNA 
shRNA (HUDEP-1 cells were used as control).  GAPDH was used as loading control.  
(B) Naïve HUDEP-2 cells, and cells transduced with scrambled and HMI-lncRNA 
shRNAs were stained with anti-HBG antibody, followed by secondary antibody labeled 
with Alexa Fluor-594 (in red) and DAPI to stain nuclei (in blue), and imaged with a 
fluorescent microscope at 40X magnification. 
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In addition to analyzing the effect of downregulating HMI-LNCRNA in non-
differentiated HUDEP-2 cells, after the two-week selection for transduced cells with 
puromycin treatment, the cells were allowed to undergo erythroid maturation for up to 
seven days (Figure 3.4).  HBG was significantly higher at Days 0, 5 and 7 in HUDEP-2 
cells with HMI-lncRNA shRNA, and HBB was significantly higher at Day 0 and 7 with 
knockdown of HMI-LNCRNA (Figure 3.5A).  HBG expression remained at about 20% of 
total HBG and HBB transcripts at each timepoint (Figure 3.5B).  These observations 
were also seen at the protein level (Supplemental Figures 3.6 and 3.7). 
 
 
           
 
Figure 3.4.  Timeline for infection and culture of HUDEP-2 cells. 
Cells were maintained in expansion medium for 2 weeks after transduction, and then 
placed in differentiation medium for up to 7 days.  Doxycycline (DOX) was removed at 
Day 5 to promote erythroid maturation. 
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Figure 3.5.  HBG and HBB expression during erythroid differentiation of HUDEP-2 
cells with knockdown of HMI-LNCRNA. 
Cells were maintained in expansion medium for 2 weeks after transduction, and then 
placed in differentiation medium for up to 7 days.  Doxycycline (DOX) was removed at 
Day 5 to promote erythroid maturation.  (A) Relative quantity for HBG and HBB 
transcripts were analyzed by qPCR in naïve HUDEP-2 cells (n=3), and cells transduced 
with scramble shRNA (n=3) and HMI-lncRNA shRNA (n=3) at Day 0, 5 and 7 of 
differentiation.  (B) Percent hemoglobin of HBG to HBB was determined by qPCR.  For 
all qPCR analyses, ACTB was used as the endogenous control. p-values:  *< 0.05; **< 
0.005; ***<0.0005; NS (not significant).  p-values were obtained by Student T-test. 
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3.2.5 The effect of knocking down HMI-LNCRNA on the transcription factors that 
regulate the expression hemoglobin 
As mentioned in Chapter 1, various transcriptions factors regulate hemoglobin 
gene expression.  Since a significant change in γ-globin expression is observed with 
downregulation of HMI-LNCRNA, the expression pattern of a few of these transcription 
factors were studied in HUDEP-2 cells transduced with naïve and scrambled shRNA 
controls and HMI-lncRNA shRNA.  The expression of KLF1, BCL11A, ZBTB7A, CHD4, 
NR2C1, NR2C2 and KDM1α, all of which were known to downregulate HBG, were 
analyzed by qPCR.  Expression of these genes was either unchanged or slightly 
upregulated in HUDEP-2 cells transduced with HMI-lncRNA shRNA compared to 
controls (Figure 3.6).  This suggests that the significant increase in γ-globin gene 
expression when HMI-LNCRNA is reduced in HUDEP-2 cells is independent of the 
expression of the transcription factors analyzed by qPCR. 
3.2.6 The effect of knocking down HMI-LNCRNA on erythroid maturation 
HUDEP-2 cells are characterized as basophilic erythroblasts expressing both 
transferrin receptor (CD71), a cell surface marker for immature erythroblasts, and 
glycophorin A (CD235), a cell surface marker for more mature erythroblasts.31  The 
percentage of cells positive for these markers were examined by flow cytometry in naïve 
cells, cells expressing scrambled shRNA and cells expressing HMI-lncRNA shRNA 
(Figure 3.7A).  Within both control groups, approximately 55-65% of the cells were 
positive for both CD71 and CD235, while about 85% of cells transduced with HMI-
lncRNA shRNA were positive for both markers, which was significantly higher than 
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control groups (Figure 3.7B).  These observations suggest that downregulation of HMI-
LNCRNA promotes maturation of HUDEP-2 cells. 
 
 
 
 
Figure 3.6.  The effects of knocking down HMI-LNCRNA on erythroid-regulating 
transcription factors in HUDEP-2 cells. 
Relative expression of KLF1, BCL11A, ZBTB7A, CHD4, NR2C1, NR2C2 and KDM1a 
transcripts were analyzed by qPCR in naïve HUDEP-2 cells, and cells infected with 
scrambled shRNA and HMI-lncRNA shRNA.  Beta actin was used as the endogenous 
control.  p-values:  *< 0.05; **< 0.005; ***<0.0005; NS (not significant).  p-values were 
obtained by Student T-test. 
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Figure 3.7.  The effects of knocking down HMI-LNCRNA on erythroid maturation 
of HUDEP-2 cells. 
(A) Naïve HUDEP-2 cells, and cells transduced with scrambled shRNA and HMI-
lncRNA shRNA (cultured in expansion medium) were stained with PE-labeled transferrin 
receptor (CD71) and PerCP/Cy5.5-labeled glycophorin-A (CD235) antibodies, and 
analyzed by flow cytometry to discriminate between cells that are positive and negative 
for GFP, CD71 and CD235.  Data was analyzed with FlowJo.  (B) Average percent 
GFP+, CD71+/CD235- and CD71+/CD235+ for each group was plotted on a bar graph. 
p-values:  *< 0.05; **< 0.005; ***<0.0005; NS (not significant).  p-values were obtained 
by Student T-test. 
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3.3 Overexpression of HMI-LNCRNA in erythroid cells 
Knocking down HMI-LNCRNA significantly increases expression of HBG.  To 
ascertain the effects of overexpressing HMI-LNCRNA, full-length HMI-LNCRNA was 
cloned into pLVX-EF1a-IRES-ZsGreen1 expression lentivector (ZsGreen lentivector), 
which co-expresses ZsGreen1, a fluorescent protein that can be detected by flow 
cytometry.  After successfully cloning HMI-LNCRNA in this ZsGreen lentivector 
(ZsGreen HMI-lncRNA), it was used to transduce HUDEP-1 cells, which, unlike 
HUDEP-2 cells, express mostly HBG and have lower expression of HMI-LNCRNA.  
Unlike pGreenPuro lentivector, ZsGreen lentivector contains no genomic cassette for 
antibiotic selection in cell culture.  Therefore, two days after transduction, cells were 
sorted for ZsGreen-positive (ZsGreen+) cells at the Flow Cytometry Core and cultured for 
two more weeks for analyses.  Naïve cells and cells transduced with vector alone 
(ZsGreen) were used as controls.  Similar to the knockdown experiments, the percent 
ZsGreen+ cells was checked by flow cytometry and showed 0% for naïve, 84% for 
ZsGreen and 88% for ZsGreen HMI-lncRNA (Supplemental Figure 3.7).  qPCR 
analysis for expression of HMI-LNCRNA showed over a 2000-fold increase in expression 
compared to naïve and ZsGreen cells allowing further analyses as most of the cells were 
transduced with either ZsGreen or ZsGreen HMI-lncRNA, and there was significant 
upregulation of HMI-LNCRNA (Figure 3.8A). 
We hypothesized that when HMI-LNCRNA is overexpressed in HUDEP-1 cells, 
MYB would increase and HBG will decrease.  However, among the three groups of 
cells—naïve, ZsGreen and ZsGreen HMI-lncRNA—there was no difference in HBG, 
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HBB, HBS1L or MYB (Figure 3.8B).  It is not necessarily true that overexpressing a gene 
will give the opposite outcome to knocking down a gene.  It is possible that other 
components that work with HMI-LNCRNA to regulate HBG expression are not expressed 
in HUDEP-1 cells, and therefore overexpressing HMI-LNCRNA will not show any effect. 
                         
 
Figure 3.8.  The effects of overexpressing HMI-LNCRNA on the expression of HBG, 
HBB, MYB and HBS1L in HUDEP-1 cells. 
Expression levels of (A) HMI-LNCRNA and (B) HBG, HBB, MYB and HBS1L were 
determined by qPCR in HUDEP-1 cells that were not transduced (naïve), and transduced 
with either ZsGreen or ZsGreen HMI-lncRNA lentiviruses by qPCR.  ACTB was used as 
the endogenous control.  p-values:  *< 0.05; **< 0.005; ***<0.0005; NS (not significant).  
p-values were obtained by Student T-test. 
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3.4 Summary and Conclusions 
To determine the effect of modulating HMI-LNCRNA on neighboring protein-
coding genes, HBS1L and MYB, and HBG and HBB in erythroid cells, we knocked down 
and overexpressed this lncRNA in HUDEP-2 and HUDEP-1 cells that produce primarily 
adult and fetal globins, respectively.  To downregulate HMI-LNCRNA, HUDEP-2 cells 
were transduced with lentiviral particles that express an shRNA template targeting the 
lncRNA.  After confirming successful transduction of cells and significant reduction of 
HMI-LNCRNA, we observed that these cells also displayed high upregulation of γ-globin 
at both the mRNA and protein levels, and a higher population of mature erythroid cells 
compared to cells in the naïve and scrambled shRNA control groups.  Furthermore, there 
was consistent upregulation and percent HBG of total HBG and HBB during 
differentiation of these cells.  Thus, these results suggest that HMI-LNCRNA regulates the 
expression of HBG and erythroid maturation (Figure 3.9).  Overexpression HMI-
LNCRNA in HUDEP-1 cells, despite a high level of cell transduction and increase in 
HMI-LNCRNA, was not accompanied by a change in the expression of MYB and globin 
genes. 
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Figure 3.9.  Model for the function of HMI-LNCRNA. 
HMI-LNCRNA is expressed from the enhancer region of MYB.  Downregulation of HMI-
LNCRNA increased the expression of HBG and promoted erythroid maturation.  Further 
investigation is required to determine if HMI-LNCRNA also regulates the expression of 
MYB. 
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3.5 Materials and Methods 
3.5.1 Development of shRNA plasmids for knockdown of HMI-LNCRNA 
Three different shRNA templates were made to target three different areas of 
HMI-LNCRNA.  This was accomplished by using Block-iT™ RNAi Designer (Life 
Technologies), which analyzed the genomic region of HMI-LNCRNA and designed 
shRNA templates that are ranked based on the likelihood that it is effective.  I used the 
top three ranking shRNA templates and labeled them HBS1L-MYB Intergenic Transcript 
1 (HMIT-1), HMIT-2 and HMIT-3.  Top and bottom strands of each shRNA were 
synthetically made (Table 3.2). 
Table 3.1.  shRNA templates for HMI-LNCRNA 
shRNA 
Template 
 
HMIT-1 
Top strand 5’- GATCCGCTAGTATGTGAAGCACTTAGCTTCCTGTC AGACTAAGTGCTTCACATACTAGCTTTTTG-3’ 
Bottom Strand 5’- AATTCAAAAAGCTAGTATGTGAAGCACTTAGTCTG ACAGGAAGCTAAGTGCTTCACATACTAGCG-3’ 
Location (ch6, hg38) 135096650-135096670 
HMIT-2 
Top strand 5’- GATCCGCCGCTGCCTTTAATTGATGTCTTCCTGTCA GAACATCAATTAAAGGCAGCGGCTTTTTG-3’ 
Bottom Strand 5’- AATTCAAAAAGCCGCTGCCTTTAATTGATGTTCTG ACAGGAAGACATCAATTAAAGGCAGCGGCG-3’ 
Location (ch6, hg38) 135096889-135096909 
HMIT-3 
Top strand 5’- GATCCGCACCATCATGGTTTCAGTGCCTTCCTGTCA GAGCACTGAAACCATGATGGTGCTTTTTG-3’ 
Bottom Strand 5’- AATTCAAAAAGCACCATCATGGTTTCAGTGCTCTG ACAGGAAGGCACTGAAACCATGATGGTGCG-3’ 
Location (ch6, hg38) 135097331-135097351 
 
Each shRNA template contained the following regions:  sense, loop, antisense and 
terminator.  Also, restriction sites for BamHI and EcoRI were placed on the 5’-end of the 
top strand and the bottom strand, respectively, to ligate shRNA templates to the 
  
69 
pGreenPuro expression lentivector (System Biosciences).  Next, the top strand and 
bottom strand of each shRNA template were annealed to make double-stranded 
oligonucleotides by incubating both strands at 95°C in annealing buffer (100 mM Tris-
HCL, 10 mM EDTA, 1 M NaCl and H2O) for 4 minutes.  The end products are double-
stranded shRNA templates with restriction sites overhangs. 
We next ligated each shRNA individually to pGreenPuro shRNA expression 
lentivector.  pGreenPuro is an HIV-based expression lentivector with the following 
attributes:  H1 promoter that is bound by RNA polymerase III for transcription of 
shRNA; EF1α promoter that expresses both GFP and puromycin-N-acetyl transferase in 
transduced cells; RSV-5’LTR to express high levels of lentiviral particles in 293T cells; 
cPPT, GAG and LTRs, which are required for packaging, transduction and integration of 
viral components; ampicillin-resistance gene for selection in competent cells; and SV40 
polyadenylation, which ensures termination of transcription.  pGreenPuro lentivector was 
linearized by restriction digest with both BamHI and EcoRI, and then ligated to each of 
the double-stranded shRNA templates.  After ligation, products were transformed into 
competent E. coli cells, grown overnight on LB plates treated with ampicillin, and 
colonies were selected and screened further by PCR to identify which clones had the 
shRNA inserts.  The following primers were used for PCR:  Forward (5’-
AATGTCTTTGGATTTGGGAATCTTAT-3’) and Reverse (5’-
TGGTCTAACCAGAGAGACCCAGTA-3’), which would amplify about a 180 bp 
product if shRNA insert is present, and a 110 bp product is insert is not present.  After 
positive clones were identified, each shRNA insert was confirmed by DNA sequencing.  
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pGreenPuro scramble shRNA (purchased from vendor, System Biosciences) was used as 
the negative control. 
3.5.2 Development of plasmid to overexpress HMI-LNCRNA 
Full-length HMI-LNCRNA was synthesized by IDT with an XbaI restriction site 
on the 5’-end and a BamHI restriction site on the 3’-end, and inserted into their pUCIDT-
AMP vector.  We next cloned HMI-LNCRNA into the pLVX-ER1a-IRES-ZsGreen1 
(ZsGreen) expression lentivector.  ZsGreen is an HIV-based expression lentivector that 
co-expresses ZsGreen, which is another green fluorescent protein.  ZsGreen have the 
same components as pGreenPuro that are necessary to cloning, lentivirus production and 
integration, except there is so antibiotic cassette to select for infected cells in culture.  
Next, both pUCIDT-AMP with HMI-LNCRNA insert and the ZsGreen underwent 
restriction digest with XbaI and BamHI to isolate and purify HMI-LNCRNA insert and to 
linearize ZsGreen.  Following digest, HMI-LNCRNA was ligated to ZsGreen, transformed 
into competent E. coli cells and cultured overnight on LB plates treated with ampicillin, 
and colonies were selected and screened further by restriction digest to identify which 
clones had the HMI-LNCRNA insert.  DNA sequencing was utilized to confirm insert-
positive clones, which was labeled as ZsGreen HMI-lncRNA.  The ZsGreen vector alone 
was used as a negative control. 
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3.5.3 TF-1a cells 
TF-1a cells are immortalized erythroblasts derived from the bone marrow of a 
patient with erythroleukemia.135  Cells are cultured at 37°C in RPMI medium containing 
10% FBS and 2% penicillin/streptomycin. 
3.5.4 HUDEP cells 
Human umbilical cord blood-derived erythroid progenitor (HUDEP) cells are 
immortalized erythroid cell lines derived from cord blood CD34+ mononuclear cells.133  
HUDEP-1 and HUDEP-2 cells were cultured at 37°C maintained in StemSpan SFEM 
medium (StemCell Technologies) supplemented with SCF (50 ng/ml, Invitrogen), EPO 
(3 U/ml, Invitrogen), dexamethasone (1 µM, Sigma), doxycycline (1 µg/ml, Clontech), L-
glutamine (1%, Life Technologies) and penicillin/streptomycin (2%, Life Technologies).  
For erythroid maturation, cells were cultured at 37°C in IMDM medium (Invitrogen) 
supplemented with heat inactivated human serum from human male AB plasma (5%, 
Sigma), EPO (3 U/ml, Invitrogen), insulin (10 µg/ml, Sigma), doxycycline (1 µg/ml, 
Clontech), holo-transferrin (500 µg/ml, Sigma), heparin (3 U/ml, Sigma), SCF (100 
ng/ml, Invitrogen), L-glutamine (1%, Life Technologies) and penicillin/streptomycin 
(2%, Life Technologies) for 5 days.  For further erythroid maturation, doxycycline was 
removed and cells were cultured for two more days. 
3.5.5 Quantitative PCR 
qPCR, also known as real-time PCR, is a tool used to quantitate the relative 
transcript levels of a specific RNA.  In the PCR phase, gene-specific primers are used to 
  
72 
amplify the target during a 40-cycle reaction period (1-40).  More abundant transcripts 
are amplified at earlier cycle thresholds (Ct) values, while less abundant transcripts are 
amplified at later Ct values.  To calculate the relative quantity of a transcript-of-interest 
(TOI), we take difference between Ct of TOI and Ct of endogenous control, such as 
ACTB (β-actin), to get ΔCt (CtTOI – CtACTB = ΔCtTOI).  Finally, the relative quantity of 
TOI is calculated using 2(-(ΔCt)).  To calculate fold change between two samples—sample 
1 (S1) and sample 2 (S2)—another approach is taken.  For each sample, we calculate 
ΔCtTOI followed by calculating ΔΔCtTOI for each sample—for S1, [(ΔCtTOI for S1) – 
(ΔCtTOI for S1)] = (ΔΔCtTOI for S1) = 0; and for S2, [(ΔCtTOI for S2) – (ΔCtTOI for S1)] = 
(ΔΔCtTOI for S2).  The fold change of the TOI for each sample is calculated using 2(-
(ΔΔCt)), in which S1 will equal 1. 
Total RNA, TaqMan primers and reagents from the TaqMan RNA-to-CT 1-Step 
Kit (Applied Biosystems) were used to make 20 µl reaction mix for each sample (done in 
triplicate) that was loaded onto a 96-well plate, following manufacturer’s instructions.  
The following TaqMan gene expression assays (Applied Biosystems) were used:  
HBG1/2 (Hs00361131_g1), HBB (Hs00758889_s1), MYB (Hs00920556_m1), HBS1L 
(Hs04188641_g1), HMI-LNCRNA (custom TaqMan assay designed by Applied 
Biosystems to target genome position chr6: 135096354-135097644, hg38; assay ID 
number AJI1MTQ), BCL11A (Hs01093197_m1), CHD4 (Hs00172349_m1), KLF1 
(Hs00610592_m1), ZBTB7A (Hs00252415_s1), NR2C1 (Hs00915957_m1), NR2C2 
(Hs00991824_m1), KDM1a (Hs01002741_m1) and ACTB (Hs01060665_g1).  QPCR 
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reactions were ran on a StepOne Plus qPCR machine (Applied Biosystems).  ACTB was 
used as the endogenous control. 
3.5.6 293T cells 
293T cells are a sub-line of 293 cells, which are immortalized human embryonic 
kidney cells.  293T cells are competent for replicating plasmids carrying SV40 origin of 
replication, and are used to produce high titers of pseudoviral particles such as lentivirus.  
They are cultured at 37°C in DMEM supplemented with 10% FBS and 2% 
penicillin/streptomycin. 
3.5.7 HT1080 cells 
HT1080 cells are derived from human fibrosarcoma, and are cultured at 37°C in 
DMEM supplemented with 10% FBS and 2% penicillin/streptomycin.  HT1080 cells can 
efficiently be transduced with lentiviruses, and therefore are used to determine viral titer. 
3.5.8 Generation of lentiviral particles 
For shRNA experiments, 293T cells were transfected with scrambled shRNA and 
HMI-lncRNA shRNA using the LentiStarter 2.0 kit (System Biosciences), which uses 
pPACKH1 lentivector packaging system, following manufacturer’s instructions, to 
generate lentiviral particles.  For overexpression experiments, 293 T cells were 
transfected with either ZsGreen vector or ZsGreen HMI-lncRNA plasmid using the 
Lenti-X Packaging Single Shots, following manufacturer’s instructions, to generate 
lentiviral particles. 
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Viral titer was determined using HT1080 cells—1x105 cells were transduced with 
various amount of lentivirus using polybrene, and GFP-positivity was determined 48 
hours later by flow cytometry.  Transducing units per mL were determined using the 
following equation:  ((1x105 x %GFP-positive cells) x 1000)/Lentivirus volume (µL). 
3.5.9 Lentivirus transduction 
For shRNA experiment, HUDEP-1 and HUDEP-2 cells were transduced at an 
multiplicity of infection (MOI) 50 with 5 µg/mL polybrene, and centrifuged at room 
temperature for 30 minutes at 1250 x g, and repeated again 48 hours later.  48 hours post-
transduction, cells were cultured in expansion medium with 1 ug/mL puromycin for up to 
two weeks to select for transduced cells.  After 2 weeks, FACS for GFP expression was 
done to ensure most cells were GFP-positive, and therefore express the shRNA plasmids. 
For overexpression experiments, HUDEP-1 cells were transduced with either ZsGreen or 
ZsGreen HMI-lncRNA at an MOI of 50 with 5 µg/mL polybrene, and centrifuge at room 
temperature for 30 minutes at 1250 x g.  Two days after transduction, cells were collected 
and sorted for GFP+ cells using flow cytometry.  After sorting, cells were cultured in 
expansion medium for up to two weeks to provide sufficient cells for analyses.  After 2 
weeks, FACS for ZsGreen expression was done to ensure most cells were infected. 
3.5.10 Cell surface staining for FACS 
5x105 cells were harvested and washed in FACS buffer.  Cells were resuspended 
in 100 µl of FACS buffer with antibody, and incubated on ice for 30 minutes.  Next, cells 
were washed twice in FACS buffer by centrifugation at 300 x g for 5 minutes each.  
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Finally, cells were fixed in IC Fixation buffer (eBioscience) for 30 minutes before 
analyzing the cells using the BD FACScan.  The following antibodies were used:  CD71-
PE (334105, BioLegend) and CD235-PerCP/Cy5.5 (306613, BioLegend). 
3.5.11 Western blot analysis 
Culture cells were centrifuged at 300 x g for 10 minutes at 4°C, washed in cold 
1X PBS and centrifuged again at 300 x g for 10 minutes at 4°C.  Cell pellets were 
suspended in Roche lysis buffer (protease inhibitor, 0.3% NP40, 10% glycerine, 2 mM 
EDTA, 246 mM NaCl, 10% phosphatase inhibitor, PBS and water), placed on ice for 1 
hour and centrifuged at 14,500 rpm for 15 minutes at 4°C to extract protein. 
For Western blot analysis, protein lysates (10 µg) were denatured with lithium 
dodecyl sulfate (LDS; Life Technologies), reduced in sample reducing agent (Life 
Technologies) and incubated at 70°C for 10 minutes.  Samples were ran on 4-12% Bis-
Tris protein gel (Life Technologies) in 1X MED SDS running buffer and 1 ml NuPAGE 
antioxidant (Life Technologies) at 200 volts for 40 minutes.  Protein from the Bis-Tris 
gel was transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad) in 
transfer buffer (2X NuPAGE transfer buffer, 10% methanol, 1 ml NuPAGE antioxidant 
and H2O) at 100 volts for 1 hour in a transfer cell kept cold with an ice package and ice.  
After transfer, membranes were immersed in Ponceau S solution (Sigma) to determine if 
transfer was successful and to cut membrane evenly to probe with different antibodies 
that recognize proteins of different molecular weights.  The following steps were taken to 
probe membrane with antibodies (all done on a rocker at 5-6 rpm at room temperature):  
wash in 1X PBS-tween 3 times for 5 minutes each; block in 1X PBS-tween with 5% milk 
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for 1 hour; wash in 1X PBS-tween; probe in primary antibody in 1X PBS with 5% milk 
for 2 hours; wash in 1X PBS-tween 3 times for 5 minutes each; probe in secondary 
antibody in 1X PBS-tween for 1 hour; and wash in 1X PBS-tween 3 times for 5 minutes 
each.  Last, the membranes were treated with enhanced chemiluminescence (ECL) 
substrate for 5 minutes, and then exposed by chemiluminescence using a LAS-4000 
Luminescent Image Analyzer at various exposure times.  The following antibodies were 
used:  c-Myb (ab109127, Abcam), hemoglobin β (16216-1-AP, Proteintech), hemoglobin 
γ (sc-21756, Santa Cruz Biotechnology) and GAPDH (sc-47724, Santa Cruz 
Biotechnology).  For densitometry, ImageJ software was used to analyze western blots to 
determine percent intensity of each band, which was used to calculate the relative 
densities.  Relative densities for c-Myb, hemoglobin beta and hemoglobin gamma were 
adjusted by GAPDH. 
3.5.12 Slide preparation for microscopy 
Cells were rinsed in PBS and resuspended in 2% BSA (in PBS).  200 µL of cell 
suspension (5-7x104 cells) were added to a cytology funnel in a slide holder and 
centrifuged in a cytospin at 800 rpm for 5 minutes.  Cells were allowed to dry on slide for 
at least 30 minutes, and then fixed in 100% methanol for 10 minutes.  Slides were stored 
at 4°C. 
3.5.13 Wright-Giemsa staining 
Fixed cells on slides were placed in diluted (1:3) Wright-Giemsa Stain (RICCA 
Chemical) for up to 1 hour.  Slides were rinsed, dried and mounted with Permount 
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(Fisher).  Images were taken in bright field with the Eclipse Ci (Nikon) microscope with 
a DS-Fi-U3 color-type (Nikon) camera, using NIS-Elements Br Imaging software 
(Nikon). 
3.5.14 Immunofluorescence 
Fixed cells were washed in PBS, blocked in 5% BSA (in PBS) and incubated in 
primary antibody for 1 hour.  Cells were washed, blocked in 5% normal goat serum and 
incubated in secondary fluorescent-labeled antibody for 30 minutes.  Finally, cells were 
washed and covered with mounting medium containing DAPI.  Images were taken with 
the Eclipse Ci (Nikon) microscope with a DS-Qi1Mc-03 mono-type (Nikon) camera, 
using NIS-Elements Br Imaging software (Nikon).  The following antibodies were used:  
Hemoglobin γ (sc-21756, Santa Cruz), Monoclonal Mouse Anti-human β-globin (a gift 
from IsoLab), Anti-human alpha globin (Wallac Inc.), and Alexa Fluor-594-conjugated 
AffiniPure F(ab)2 Fragment Goat Anti-mouse IgG (H+L) (115-586-062, Jackson 
ImmunoResearch). 
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CHAPTER 4.  DISCUSSION 
4.1 The HBS1L-MYB Intergenic Long Noncoding RNA (HMI-LNCRNA) 
The HBS1L-MYB intergenic region on chr6q23 is important for regulating 
erythroid-specific traits.  It contains an enhancer for the downstream gene MYB and 
binding sites for erythroid-specific transcription factors, which all bind to the promoter of 
MYB to increase its transcription.  Furthermore, it is also known that upregulation of MYB 
increases erythroid cell proliferation, inhibits erythroid cell maturation, decreases HBG 
and increases HBB expression.  Consequently, polymorphisms found within this region 
are associated with high HbF because they disrupt the enhancer-promoter interaction, 
thus reducing MYB expression and increasing expression of HBG and HbF.  This doctoral 
work adds another element to this intergenic region, a novel 1283 bp lncRNA (chr6: 
135096362-135097644, hg38) that is transcribed from the enhancer of MYB, and contains 
the HbF-associated polymorphic region rs66650371.  Further characterization of HMI-
LNCRNA revealed that it is not erythroid-specific but might be hematopoietic-specific; is 
located in the nucleus; is expressed at very low levels compared to the protein-coding 
gene MYB, and it is expressed at significantly higher levels in erythroid cells expressing 
HBB compared to cells that expressing HBG.  The expression pattern of HMI-LNCRNA 
in these cells is similar to that of MYB. 
Since HMI-LNCRNA is transcribed from an enhancer regulatory element for 
MYB, this suggests that it functions as an eRNA to support and promote binding of the 
erythroid-specific transcription factors to the promoter of MYB.  However, additional 
experimentation will have to be done to determine if HMI-LNCRNA does work in 
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complex with these transcription factors.  One method that can be used is chromatin 
isolation by RNA purification sequencing (ChIRP-seq).136  ChIRP-seq is a relatively new 
approach to determine which genomic regions and proteins bind to a specific lncRNA.  It 
crosslinks genomic DNA and proteins that are bound to lncRNA, adds biotinylated tilling 
oligonucleotides to bind to the lncRNA of interest, and then purifies out the complex by 
using magnetic beads to pull out the biotinylated oligonucleotides that are attached to the 
lncRNA.  After purification, the complex can be dissociated and further analyses can be 
done to determine which genomic region and proteins bound to the lncRNA.  If HMI-
LNCRNA does function as an eRNA to promote the expression of MYB, we should find 
that it is associated with the promoter of MYB, and binds to TAL1/E47, RUNX1, GATA, 
LDB1 and KLF1.  It is also possible for HMI-LNCRNA to regulate other protein-coding 
genes either in cis or trans, which ChIRP-seq will be able to elucidate. 
We observed that the expression pattern of HMI-LNCRNA decreases during 
erythroid differentiation, as does the expression pattern of MYB.  It will also be 
informative to determine the expression pattern of HMI-LNCRNA during the earlier phase 
of hematopoiesis, such as the HSCs, the common myeloid progenitors (CMPs) and the 
common lymphoid progenitors (CLPs) to determine if expression differs from that of 
erythroblasts.  Since the expression of MYB is higher in HSCs, CMPs and CLPs, I would 
hypothesize that HMI-LNCRNA will be higher in these cells as well.27  Additionally, 
MYB is not expressed during primitive erythropoiesis.2  Therefore, it will also be of 
interest to determine if HMI-LNCRNA is not expressed in primitive erythroid cells. 
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4.2 HMI-LNCRNA and HbF 
Increasing HbF levels in individuals with SCD is a major goal of clinical 
treatment.  Hydroxyurea, which was the first FDA-approved drug for SCD, blood 
transfusions and gene therapy, are either not effective in all patients or financially and 
physically taxing.  Therefore, it is vital to better understand how hemoglobin expression 
can be regulated in order to lead the field to more effective therapeutic treatments that 
will promote the expression of HbF.  Various transcription factors such as BCL11A, 
KLF1 and LRF have been discovered to regulate HbF, and are considered possible 
therapeutic targets.31,137,138  Once thought of as “junk” RNA, lncRNAs are now 
considered to be important regulators of cellular processes, biomarkers for disease 
prognosis and possible therapeutic targets for disease treatment.  This provides a rationale 
for further study of lncRNAs and erythroid ontogeny.  Published data implicate lncRNAs 
as important regulators of hematopoiesis and erythropoiesis, however, before my studies, 
none have been implicated as regulators of hemoglobin expression.  Therefore, it was 
very interesting and exciting to see that when HMI-LNCRNA was downregulated in 
HUDEP-2 cells, γ-globin expression increased both at the mRNA and protein levels.  
HUDEP-2 cells have been used to study the regulation of hemoglobin expression and 
erythroid maturation.31,137  However, additional functional analyses will be necessary in 
other cell culture systems, such as induced pluripotent stem cells (iPSCs)139 and primary 
erythroid cells derived from CD34+ mononuclear cells, to ensure these results can be 
replicated in cells of different genetic backgrounds and normal cells directly from human 
tissue.  Also, we can determine if the upregulation of HBG provides sufficient HbF to 
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inhibit polymerization of sickle hemoglobin after knockdown of HMI-LNCRNA, which 
will clinically benefit patients with SCD. 
As mentioned in Chapter 3, gene editing is a tool used to stop transcription by 
removing genomic regions where genes are transcribed.  In early work, investigators used 
gene editing to remove lncRNAs in order to determine their function.  However, it has 
been discovered that removal of these genomic regions, which are mostly in intergenic 
regions, not only inhibits transcription of the lncRNA, but also removes regulatory 
regions that regulate the expression of neighboring genes.  Paralkar et al determined if the 
lncRNA, Lockd, actually does regulate the transcription of its neighboring gene, Cdkn1b, 
as was suggested in the literature.140  Therefore, gene editing was used in two different 
experiments to delete the entire Lockd gene, and to stop transcription of Lockd by placing 
a polyadenylation signal at its transcription start site.  When Lockd is deleted from the 
genome, there was low expression of Cdkn1b.  However, when a polyadenylation signal 
was inserted at the transcription start site of Lockd, thus inhibiting its transcription, 
Cdkn1b was transcribed normally.  They further showed that Lockd resided within an 
enhancer region for Cdkn1b, and when the region was deleted, it reduced expression of 
this gene.  However, if the genomic region was left basically intact and only the 
transcription of the lncRNA was inhibited by inserting a polyadenylation signal, there 
was no change in Cdkn1b expression.  This suggested that Lockd did not regulate Cdkn1b 
and that previously published work was likely to be incorrect.  A similar approach would 
have to be taken if we stop transcription of HMI-LNCRNA.  Since shRNA does not 
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entirely knockdown HMI-LNCRNA, and since gene editing can fully curtail its 
expression, without residual lncRNA, a significant downregulation of MYB might occur. 
4.3 Generating a Mouse Model for HMI-LNCRNA 
If downregulation of HMI-LNCRNA can be confirmed to significantly increase 
HbF in primary erythroid cells to levels that could be therapeutically useful, the next step 
to consider is developing a mouse model for this lncRNA.  Investigators have used 
various methods to determine the functionality of lncRNAs via mouse models that are 
similar to mouse models of protein coding genes.  Xenograft models have been useful in 
determining if neoplastic cells with a specific genetic modification have the ability to 
grow and/or metastasize in immunocompromised mice.107  Many lncRNAs have been 
discovered to be involved in the pathophysiology of specific cancers, and therefore this 
approach is frequently used.  Another methodology is treating mice with antisense 
oligonucleotides (ASOs) that will bind to and thus reduce the amount of the specific 
lncRNA targeted.141  If ASOs were used for HMI-LNCRNA, this could be a preclinical 
model, which could possibly translate to the clinic as an approach for drug development 
for patients with SCD.  Transgenic mouse models also have been useful for studying 
disease pathophysiology and treatment.142 
To study HMI-LNCRNA in vivo, there are two approaches to consider, and both 
include using the sickle cell transgenic mouse model.143  The first approach is to treat the 
SCD mice with ASOs for hmi-lncrna, and determine if HbF increases.  The second 
approach is to make an hmi-lncrna knockout mouse and cross it with an SCD mouse, and 
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determine if HbF increases in these mice, and if it is enough to inhibit polymerization of 
HbS. 
There are a couple factors to consider before developing a mouse model for hmi-
lncrna, and the first requires that it be expressed in the mouse.  There is a lncRNA 
annotated in the mouse genome (Gm33728; chr10: 21228529-21252242; mm10) that is 
23.7 kb in length.  Human HMI-LNCRNA maps to an intron of Gm33728, and therefore 
they do not correspond to each other.  However, it does not mean they do not have 
similar functions.  There is no published data on Gm33728, therefore it will be of interest 
to determine if Gm33728 can regulate the expression of myb and hemoglobin as well.  
Another factor to consider is murine hemoglobin expression.  Mice do not express HbF, 
but they do have embryonic hemoglobin, and it will be interesting to determine if 
Gm33728 regulates its expression.143 
4.4 HMI-LNCRNA as a Therapeutic Target 
The severity of symptoms related to SCD is correlated not only to whether a 
patient express high levels of HbF, but also the HbF concentration in sickle erythrocytes 
and the distribution of HbF amongst F-cells.144  Therefore, it is important to know if 
reduction of HMI-LNCRNA will increase HbF to levels that are beneficial to SCD 
patients.  Knockdown of HMI-LNCRNA in HUDEP-2 cells resulted in an increase of 
HBG to 20% of the total HBG and HBB transcripts.  Furthermore, this led to detectable 
protein expression of HBG.  But will that ameliorate symptoms of SCD?  HUDEP-2 cells 
also displayed a heterocellular expression pattern of HBG when HMI-LNCRNA was 
downregulated, which reflected a phenotype found in patients with (δβ)0-thalassemia.  As 
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mentioned in Chapter 1 (subsection 1.3.1), (δβ)0-thalassemia and HPFH vary both in the 
concentration and distribution of HbF among RBCs.70  These variations are the reason 
why patients with (δβ)0-thalassemia are symptomatic and patients with HPFH are not.  
Therefore, the heterocellular distribution of HbF found in HUDEP-2 cells when HMI-
LNCRNA was downregulated is not ideal when considering it as a therapeutic target.  
However, there were factors in the experiment that would have caused this uneven 
expression pattern of HbF.  Transduction of HUDEP-2 cells with lentiviral particles is not 
homogenous.  Therefore, not every cell expressed the same copy number of shRNA 
template.  This suggests that cells with more copies of HMI-lncRNA shRNA expressed 
more HBG than cells with fewer copies.  One way to address this issue is to undertake 
clonal expansion from a single cell after transduction. 
4.5 Summary 
The specific aims of my doctoral thesis was to characterize a transcript found 
within the HBS1L-MYB intergenic region on chr6q23, and to determine its function as it 
relates to the expression of MYB and hemoglobin.  I discovered a novel 1283 bp lncRNA, 
named the HBS1L-MYB intergenic lncRNA (HMI-LNCRNA), which is transcribed from 
an intergenic region important for the regulation of erythroid-associated traits, and has 
been found to significantly increase γ-globin expression at both the mRNA and protein 
levels when downregulated by shRNA.  Furthermore, due to this remarkable increase in 
γ-globin expression, HMI-LNCRNA can be considered as a possible therapeutic target for 
individuals with SCD and β-thalassemia where increased HbF is clinically beneficial. 
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SUPPLEMENTAL DATA 
 
 
 
                      
Supplemental Figure 2.1.  Sequencing results for 3’-RACE PCR product. 
Position 571 of sequencing results was the last nucleotide aligned on chr6q23 of NCBI 
Blast results, which is 135097644 (hg38). 
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Supplemental Figure 2.2.  Sequencing results for 5’-RACE PCR product. 
Position 32 of sequencing results was the last nucleotide aligned on chr6q23 of NCBI 
Blast results, which is 135096362 (hg38). 
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Supplemental Figure 2.3.  Expression pattern of MYB among various human cells 
and tissue 
Relative quantity of MYB was measured my qPCR in 25 different samples.  Means are 
shown for samples with two or more independent samples.  ACTB was used as the 
endogenous control. 
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Supplemental Figure 2.4.  Hemoglobin expression in K562 cells treated with 
arginine butyrate. 
K562 cells were either untreated (n=1) or treated (n=3) with 1 mM arginine butyrate for 
seven days.  At day 7, cells were harvested to determine (A) cell color, (B) HBG mRNA 
expression by qPCR, and (C) HBG protein expression by Western blot analysis (left 
panel) and immunofluorescence staining (blue is DAPI, green is HBG).  ACTB was used 
as endogenous control for qPCR analysis. 
  
  
89 
 
         
 
Supplemental Figure 2.5.  Timeline for the expansion and differentiation of CD34+ 
cells derived cord blood and peripheral blood. 
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Supplemental Figure 3.1.  HMI-LNCRNA expression in TF-1a cells transduced with 
three different HMI-lncRNA shRNA templates. 
TF-1a cells were transduced with pGreenPuro (pGP) (n=1), and HMIT-1 (n=1), HMIT-2 
(n=1) and HMIT-3 (n=1) shRNAs and cultured for two weeks in 8 µg/ml puromycin for 
selection.  qPCR analysis for HMI-LNCRNA was analyzed to determine fold change for 
each sample.  ACTB was used as endogenous control. 
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Supplemental Figure 3.2.  HMI-LNCRNA expression in HUDEP-2 cells transduced 
with three different HMI-lncRNA shRNA templates. 
HUDEP-2 cells were transduced with pGreenPuro (pGP) (n=3), and HMIT-1 (n=3), 
HMIT-2 (n=3) and HMIT-3 (n=2) shRNAs and cultured for one week in 1 µg/ml 
puromycin for selection.  qPCR analysis for HMI-LNCRNA was analyzed to determine 
fold change for each sample.  ACTB was used as endogenous control.  p4 sample is non-
transduced HUDEP-2 cells. 
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Supplemental Figure 3.3.  FACS analysis for GFP expression in HUDEP-2 cells 
transduced with scramble shRNA and HMI-lncRNA shRNA. 
Naïve HUDEP-2 cells (n=3), and cells transduced with scramble shRNA (n=3) and HMI-
lncRNA shRNA (n=3) were fix, and analyzed by flow cytometry based on SSC-H (side 
scatter for granularity) and expression of GFP+. 
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Supplemental Figure 3.4.  GFP and HMI-LNCRNA expression in HUDEP-1 cells 
transduced with scramble shRNA and HMI-lncRNA shRNA. 
(A) Naïve HUDEP-1 cells (n=3), and cells transduced with scramble shRNA (n=3) and 
HMI-lncRNA shRNA (n=3) were fix, and analyzed by flow cytometry based on SSC-H 
(side scatter for granularity) and expression of GFP+.  (B) qPCR analysis for HMI-
LNCRNA of HUDEP-1 cells from each group.  ACTB was used as endogenous control.  
NS means not significant. 
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Supplemental Figure 3.5.  HBB and HBA expression. 
Naïve HUDEP-2 cells, and cells transduced with scramble and HMI-lncRNA shRNAs 
were stained with (A) anti-HBB antibody and (B) anti-HBA antibody, followed by 
secondary antibody labeled with Alexa Fluor-594 (in red), and DAPI to stain nuclei (in 
blue), and imaged with a fluorescent microscope at 40X magnification. 
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Supplemental Figure 3.6.  Protein expression of c-MYB and hemoglobin with 
knockdown of HMI-LNCRNA during erythroid differentiation of HUDEP-2 cells. 
Naïve HUDEP-2 cells, and cells transduced with scramble shRNA and HMI-lncRNA 
shRNA were placed in differentiation medium for up to 7 days.  Protein expression of c-
MYB, HBG and HBB were analyzed in cells from (A) Day 0, (B) Day 5 and (C) Day 7 
(HUDEP-1 cells were used as control).  GAPDH was used as loading control.  
Densitometry was used to quantify western blot results (measured by ImageJ).  p-values:  
*< 0.05; **< 0.005; ***<0.0005; NS (not significant).  p-values were obtained by 
Student T-test.  
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Supplemental Figure 3.7.  Protein expression of HBG with knockdown of HMI-
LNCRNA at Day 7 of erythroid differentiation of HUDEP-2 cells. 
Naïve HUDEP-2 cells, and cells transduced with scrambled and HMI-lncRNA shRNAs 
were placed in differentiation medium for 7 days.  Cells were stained with anti-HBG 
antibody, followed by secondary antibody labeled with Alexa Fluor-594 (in red) and 
DAPI to stain nuclei (in blue), and imaged with a fluorescent microscope at 40X 
magnification. 
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